Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers

Lucia Cerrito, Brigida Eleonora Annicchiarico, Roberto Iezzi, Antonio Gasbarrini, Maurizio Pompili, Francesca Romana Ponziani

Abstract
Hepatocellular carcinoma is one of the most frequent malignant tumors worldwide. Portal vein tumor thrombosis (PVTT) occurs in about 35%-50% of patients and represents a strong negative prognostic factor, due to the increased risk of tumor spread into the bloodstream, leading to a high recurrence risk. For this reason, it is a contraindication to liver transplantation and in several prognostic scores sorafenib represents its standard of care, due to its antiangiogenetic action, although it can grant only a poor prolongation of life expectancy. Recent scientific evidences lead to consider PVTT as a complex anatomical and clinical condition, including a wide range of patients with different prognosis and new treatment possibilities according to the degree of portal system involvement, tumor biological aggressiveness, complications caused by portal hypertension, patient’s clinical features and tolerance to antineoplastic treatments. The median survival has been reported to range between 2.7 and 4 mo in absence of therapy, but it can vary from 5 mo to 5 years, thus depicting an extremely variable scenario. For this reason, it is extremely important to focus on the most adequate strategy to be applied to each group of PVTT patients.

Key words: Portal vein tumor thrombosis; Sorafenib; Systemic chemotherapy; Transarterial chemoembolization; Transarterial radioembolization; Percutaneous ablation therapies; Combined therapies; Surgery; Liver transplantation

ORCID number: Lucia Cerrito (0000-0001-6837-7582); Brigida Eleonora Annicchiarico (0000-0002-9230-5607); Roberto Iezzi (0000-0002-2791-481X); Antonio Gasbarrini (0000-0003-4863-6924); Maurizio Pompili (0000-0001-6699-7980); Francesca Romana Ponziani (0000-0002-5924-6238).

Author contributions: Cerrito L, Pompili M and Ponziani FR were responsible for manuscript preparation, table design, reference collection and final editing; Annicchiarico BE, Iezzi R and Gasbarrini A contributed to this paper with drafting and critical revision and editing.

Conflict-of-interest statement: No potential conflicts of interest. No financial support.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Invited manuscript

Received: April 22, 2019
INTRODUCTION

Hepatocellular carcinoma (HCC) is one of the most frequent malignant tumors worldwide accounting for 749,000 new cases/year and about 745,000 deaths/year, with an incidence that ranges from less than 5 per 100,000 individuals in Northern Europe, United States and Japan to over 20 per 100,000 in sub-Saharan Africa and Eastern Asia[1-3].

Portal vein tumor thrombosis (PVTT) occurs in about 35%-50% of patients[4] and involves the main trunk at the time of diagnosis in 15%-30% of cases[5]. However, PVTT prevalence is certainly underestimated, being incidentally found in about 62% of autopic livers and in 14% of surgical specimens obtained from HCC patients[6]. In those with already known history of HCC, the probability of malignant vascular infiltration is as high as 30%, decreasing to 20% in case of contemporary diagnosis of both HCC and thrombosis[7].

The presence of PVTT is considered a strong negative prognostic factor, due to the increased risk of release into the bloodstream of cancer cells, leading to a high recurrence risk; for this reason, it is considered a contraindication to LT and is included in several HCC-prognostic scores [e.g., Barcelona-Clinic Liver Cancer (BCLC) staging system, French classification of HCC, Cancer of the Liver Italian Program (CLIP) classification, the Hong-Kong Liver Cancer (HKLC) staging system, Chinese University Prognostic Index (CUPI) score, and Japan Integrated Staging (JIS)][8-14]. In most of these classifications, sorafenib is the standard of care for patients with PVTT due to its antiangiogenetic action related to the inhibition of the vascular endothelial growth factor (VEGF). However, sorafenib can grant only a poor prolongation of life expectancy in these patients[8].

Recent scientific evidences lead to consider PVTT as a complex anatomical and clinical condition, including a wide range of patients with different prognosis and new treatment possibilities according to degree of the portal system involvement, tumor biological aggressiveness, patient’s clinical features and tolerance to antineoplastic treatments, severity of liver dysfunction, and complications caused by portal hypertension (e.g., variceal hemorrhage). The median survival has been reported to range between 2.7 and 4 mo in absence of therapy[16,17], but it can vary from 5 mo to 5 years according to liver function, tumor features and treatment applied, thus depicting an extremely variable scenario[4,8]. For this reason, it is extremely important to focus on the most adequate strategy to be applied to each group of PVTT patients.

DIAGNOSTIC APPROACH TO PVTT

Ultrasound (US) examination represents the first-line imaging technique for the detection of PVTT with sensitivity and specificity of 80%-100% and diagnostic accuracy of 88%-98%[18-20]. The thrombus appears as a hypo/isoechoic inhomogeneous material obstructing partially or completely the vessel, with an expansive aspect of the mass and difficult or absent detection of the infiltrated vascular walls. Colour and Power Doppler-US is able to detect pulsatile signs of arterial neovascularization
within the endoluminal mass, while pulsed Doppler identifies high resistance index in intrallesional arterial flow.[19]

Contrast enhanced ultrasound (CEUS) represents the most sensitive and cheap method to depict neoplastic endovascular invasion, with a better diagnostic performance compared to computed tomography (CT)-scan (sensitivity 88%-100%, specificity 94%-96% in differential diagnosis between benign and neoplastic PVTT).[21] PVTT presents a HCC-like contrast behaviour, with a rapid wash-in during arterial phase and wash-out in the portal/late phase, while benign thrombus has no contrast enhancement in all the study phases.[21]

CT-scan and magnetic resonance imaging (MRI) can distinguish between neoplastic and non-neoplastic portal thrombosis and add further information on thrombosis extension and presence of collateral vessels, with a sensitivity of 86% and 100% and a specificity of 100% and 90%, respectively. In particular, CT texture analysis and attenuation values grant the distinction between neoplastic and benign thrombosis on portal-phase CT imaging by analysing thrombus density, mean value of positive pixels and entropy.[23-27]

Percutaneous US-guided fine-needle aspiration is another simple, safe and effective diagnostic method to distinguish non-neoplastic and neoplastic portal thrombosis when a definitive diagnosis is not attained by imaging methods.[28]

Another promising tool to achieve differential diagnosis between non-malignant thrombosis and PVTT is [18]F-Fluorodeoxyglucose positron emission tomography/CT ([18]F-FDG PET/CT), which seems to be able to identify metabolic abnormalities of the thrombus before the detection of the typical morphological and contrast enhanced signs detected on CT-scan. Hu et al[29] defined thrombus malignancy by visual analysis and a maximum standardized uptake value (SUVmax) > 3.35.

CLASSIFICATION OF PVTT

PVTT classification is crucial to define a proper therapeutic approach. There are many studies describing PVTT stages according to the classifications created in different medical centers. In 2010 Ikai et al[30,31] on behalf of the Liver Cancer Study Group of Japan (LCSGJ), distinguished four grades of PVTT and three grades of hepatic vein tumor involvement [Vp1: Presence of a tumor thrombus distal to the second-order branches of portal vein (but not involving them directly); Vp2: Invasion of the second-order branches of portal vein; Vp3: Presence of the thrombus in the first-order branches; Vp4: Tumor thrombus in the main trunk of the portal vein and/or a portal vein branch contralateral to the primarily involved lobe; Vv1: Tumor thrombus in a branch of the hepatic vein; Vv2: Tumor thrombus in the main trunk of the hepatic veins; Vv3: Thrombus reaching the right atrium] (Figure 1).

Another classification proposed by Cheng et al describes the portion of portal vein involved, identifying 4 categories: Type I, indicating microscopic portal invasion, Type I combining Vp1 and Vp2, Type II corresponding to Vp3, Type III and IV indicating thrombus in the main trunk and involvement of superior mesenteric vein, respectively.[32-33]

Finally, a simplified classification, divides patients with HCC and PVTT in group A (tumor thrombus in the main portal trunk or in both the left and right portal veins) and group B (involvement of either the left or the right portal vein).[34]

TREATMENT OPTIONS FOR HCC WITH PVTT: STATE OF THE ART AND POSSIBLE FUTURE PERSPECTIVES

According to the Barcellona Clinic Liver Cancer (BCLC) classification, the recommended treatment for HCC with PVTT is sorafenib. However, many other treatment strategies have been attempted, with variable results. They include nonsurgical procedures, such as systemic chemotherapy, radiation therapy, transarterial chemoembolization (TACE), microwave coagulation therapy (MCT), percutaneous ethanol injection (PEI), radiofrequency ablation (RFA), and surgical options such as resection and liver transplantation (LT).

Sorafenib
Sorafenib is a multi-tyrosine-kinase inhibitor targeting Raf/Mek/Erk-pathways, vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors, widely used as standard-of-care in the treatment of advanced HCC.[35] Its efficacy has been investigated by two phase-III-trials: In the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP, studying Western
| Portal vein tumor thrombosis classification according to the Liver Cancer Study Group of Japan | MSTs (yr) |
|---------------------------------------------------------------|----------|
| VP 1: Tumour thrombus distal to the second-order branches of portal vein | 2.67     |
| VP 2: Invasion of the second-order branches of portal vein | 1.51     |
| VP 3: Thrombus in the first-order branches | 0.78     |
| VP 4: Tumour thrombus in main portal trunk or portal branch contralateral to primarily involved lobe (or both) | 0.50     |
| Vv1: Tumor thrombus in a branch of the hepatic vein | NA       |
| Vv2: Tumor thrombus in the main trunk of the hepatic veins | NA       |
| Vv3: Thrombus reaching the right atrium | NA       |

Figure 1 Portal vein tumor thrombosis classification according to the Liver Cancer Study Group of Japan. MSTs: Median survival times; NA: Not available.

population), the median overall survival (OS) of patients with HCC and macrovascular invasion ($n = 108$ patients) was 8.1 mo vs 4.9 mo in the placebo group ($n = 123$ patients), while time to progression (TTP) was 4.1 mo vs 2.7 mo, respectively; these results were confirmed by the Asia-Pacific Trial, but, as sorafenib was only able to slightly prolong OS compared to placebo in advanced HCC (6.5 mo vs 4.2 mo, its effect in presence of PVTT was even smaller (5.6 mo vs 4.1 mo, TTP 2.7 mo vs 1.3 mo) in this study[35-38]. Yau et al[39] noticed a similar OS in both patients with and without PVTT treated with sorafenib. Subsequent studies in patients with PVTT classified as
Vp2-3-4 did not reveal satisfying performances. Jeong et al.\(^{(40)}\) analysed the effects of sorafenib monotherapy in Vp3-4 PVTT, finding a 10% response rate and a 40% disease control rate (OS 3.1 mo; TTP 2.1 mo); the overall incidence of drug-related adverse events (AEs) was 90% and the most common AEs (grade 1-2) were dermatological, gastrointestinal and constitutional.

As regards the combination of systemic treatments with other techniques, Giorgio et al.\(^{(41)}\) demonstrated a better outcome for PVTT treated with both sorafenib and RFA compared to sorafenib alone (1-2-3 year survival rates were 60%, 35% and 26% vs 37%, 0% and 0%, respectively); AEs were almost superimposable in the two groups [abdominal pain, hand foot skin reaction (HFSR), asthenia, diarrhoea, weight loss]. A recent multicenter phase III trial by Park et al.\(^{(42)}\) demonstrated that, in advanced HCC, sorafenib combined with cTACE faced to sorafenib-alone does not achieve an increase in OS (12.8 mo vs 10.8 mo; HR = 0.91; 90%CI: 0.69-1.21; P = 0.290) but improved TTP (5.3 mo vs 3.5 mo; HR = 0.67; 90%CI: 0.53-0.85; P = 0.003), PFS (5.2 mo vs 3.6 mo; HR = 0.73; 90%CI: 0.59-0.91; P = 0.01) and tumor response rate (60.6% vs 47.3%, P = 0.005)

Surprisingly, patients with Vp3-4 PVTT or invasion of other vessels seemed to have a survival benefit from sorafenib plus TACE, even though this trend was not statistically significant (HR = 0.52; 95%CI: 0.27–1.02). It is also relevant to point out that a high incidence of serious AEs was observed in the combination treatment group faced to sorafenib-alone (33.3% vs 19.8%, P = 0.006, respectively), including elevation of alanine aminotransferase (ALT), hyperbilirubinemia, ascites, HFSR, thrombocytopenia and anorexia.

It should be noted that data on the efficacy of other antiangiogenetic drugs in patients with PVTT are lacking. Indeed, in the registrative study of lenvatinib, which has been shown to be non-inferior to sorafenib for the treatment of patients with advanced HCC, patients with main portal trunk invasion were excluded\(^{(42)}\).

**Systemic chemotherapy**

Traditional chemotherapy is not usually included in HCC treatment algorithms because of its toxicity, which may be even more serious in patients with cirrhosis and liver function impairment.

Okada et al.\(^{(43)}\) conducted a phase II study in which different systemic chemotherapy regimens [Tegafur, Doxorubicin, Tegafur plus Uracil, Etoposide, Mitoxantrone, Interferon-gamma, Cisplatin, 5-fluorouracil (5-FU)] were administered to 71 patients with unresectable HCC, whose response varied from 0% to 20%; median survival time was 5.6 mo, 1-year and 2-years survival rates were 23% and 5%. Among them, 22 patients had Vp4 PVTT, with a reported median survival time of 3.9 mo. Itamoto et al.\(^{(44)}\) assessed hepatic arterial infusion of 5-FU and cisplatin in 7 patients with unresectable HCC and Vp3-4 PVTT: Response rate was 33%; a reduction in size or disappearance of thrombosis after chemotherapy was observed in 43% patients; mean and median survival times were 8 and 7.5 mo, respectively. No serious AEs occurred, whereas nausea and vomiting were the most common mild AEs requiring medical management. Yamasaki et al.\(^{(45)}\) obtained good results in a randomized study on HCC with PVTT by the addition of leucovorin to the protocol previously experimented by Itamoto\(^{(46)}\), with a 56% response rate vs 20% (P = 0.022); indeed, for leucovorin arm, 1- and 2-year survival rates were 66.7% and 44.4% compared to 10% and 0% for the control group (P = 0.033).

Ando et al.\(^{(47)}\) examined 9 patients with advanced HCC and Vp4-PVTT for the efficacy of low-dose cisplatin and 5-FU arterial infusion by subcutaneously implanted injection-port: overall response rate was 44.4%, 3-year survival rate was 40%, median survival time 10.2 mo. Only tolerable AEs occurred (nausea, loss of appetite).

Interesting data also come from small studies using chemotherapy schemes including interferon (IFN)-alpha. Urabe et al.\(^{(48)}\) treated 16 patients with HCC and Vp3-4 PVTT with a combined scheme of methotrexate, 5-FU, cisplatin and IFN-alpha 2b; the reported response rate was 46.7%, median survival was 7 mo, and the 2-year survival rate was 57.1%. Transient severe hematologic AEs were registered and more than half of patients presented grade 2 nausea or vomiting. Similar results and safety data were described by Kaneko et al.\(^{(49)}\) using the same therapeutic regimen (overall response rate 45%, median survival 11 mo, 2-year survival 15%).

Some other studies showed encouraging results for the combination of subcutaneous IFN-alpha and intra-arterial 5-FU in the treatment of HCC with Vp3-4 PVTT: Response rates ranged from 43.6% to 63% and mean survival rates from 6.9 to 11.8 mo\(^{(50-52)}\).

Hepatic arterial infusion chemotherapy (HAIC) has been also investigated in the treatment of PVTT, because of its property to carry anticancer drug directly at the tumor site, thus limiting systemic AEs. Song et al.\(^{(53)}\) showed that HAIC was more effective than sorafenib in the treatment of Vp2-4 PVTT (OS = 7.1 mo vs 5.5 mo, P = 0.011; TTP 3.3 mo vs 2.1 mo, P = 0.034); the most common AE in the sorafenib group
was HFSR (45%, mainly grade 1-2), while in the HAIC group all patients had at least grade 1 AEs, and grade 3-4 AEs were more frequent, with 98% anemia, 84% thrombocytopenia, 74% bilirubin elevation and 72% ALT elevation (68% HAIC group vs 27% sorafenib group).

Ikeda et al\cite{54} designed a phase II trial that proved a fair efficacy of intra-arterial cisplatinfusion in Vp3-4 PVTT, with a response rate of 28\%, a mean survival time of 7.1 mo and grade 3 AEs (blood cell decrease, transient transaminases elevation) not requiring treatments. However, other similar experiences did not confirm such encouraging results\cite{55,56}.

Another interesting perspective is offered by metronomic chemotherapy protocol (MET) that should act by preventing tumor cell proliferation and angiogenesis and stimulating the immune system.

Yang et al\cite{57} compared MET with cisplatin and 5-FU to sorafenib in the treatment of advanced HCC with PVTT, finding better outcomes as regards median survival time (158 d vs 117 d) and OS rate in the first group (P = 0.029). Main AEs in the MET group were leukopenia (48\%), hyperbilirubinemia (30\%), thrombocytopenia (22\%), serum ALT elevation (17\%); in the sorafenib group, mainly skin (28\% HFSR) and gastrointestinal tract toxicity (40\%), hyperbilirubinemia (36\%) and increase in ALT serum levels (17\%) were reported. The difference between grade 3-4 toxicity rates in both groups was not statistically significant. An Italian experience\cite{58} proved that MET with capcetinabe was effective in improving patients’ survival after sorafenib discontinuation compared to best supportive care. However, in this study, patients in the MET group showed a lower prevalence of PVTT, which represented itself a negative prognostic factor.

TACE

TACE is considered the preferential palliative therapy for multinodular HCC for patients with well-preserved liver function. TACE usefulness in PVTT, especially in type III/IV, remains uncertain, because of the limited effect on survival compared to systemic treatments and the potential risk of ischemia related post-TACE liver function failure; this risk appears increased if the collateral blood circulation surrounding the obstructed portal vein is insufficient\cite{59-61}. The main studies concerning TACE in PVTT patients are summarized in Table 1.

A metanalysis by Xue et al compared TACE and conservative treatment in 1601 patients with PVTT: 6-mo and 1-year survival were better in TACE group than in supportive therapy group, with good results for both Child-Pugh A and B patients\cite{62}. These results were confirmed in another metanalysis by Leng et al\cite{63} including 600 patients.

A review by Silva et al\cite{64} including 13 studies with 1933 patients with PVTT treated with TACE, showed a 1-, 3-, 5-year survival of 29\%, 4\% and 1\%, respectively. Main trunk PVTT demonstrated the worst outcome, although the Modified Response Evaluation Criteria in Solid Tumors (mRECIST) response rates were similar in cases with main portal vein or portal vein branches thrombosis (14\% vs 16\%, P = 0.238).

Compared to conservative treatment, TACE allows to achieve a mean survival time of 19 mo vs 4 mo in type I PVTT (Vp1-2), 11.0 mo vs 1.43 mo in type II PVTT (Vp3), and 7.1/4.0 mo vs 1.3/1.0 mo in type III/IV (Vp4), respectively (P < 0.01)\cite{65}. Chung et al reported a median OS of 5.6 mo vs 2.2 mo (P < 0.001) in a study in which TACE arm was compared faced to supportive care arm. The best survival results were achieved in patients with Vp4. The AEs rate was 28.9\%, with gastrointestinal hemorrhage more frequent in the TACE group\cite{66}. Another small study evidenced satisfying survival rates at 3-, 6- and 12-mo (82\%, 71\%, 47\% respectively), with a median survival rate of 10 months in Child-Pugh A compared to Child B patients (15 mo vs 5 mo, respectively)\cite{67}. Tawada et al\cite{68} retrospectively analyzed the AEs in a group of patients with PVTT treated with TACE: The main grade 3 AEs were ALT and AST (Aspartate Aminotransferase) elevation (54.5\% and 69.7\%, respectively), whereas the occurrence of thrombocytopenia, hynotremia, hyperbilirubinemia, leukopenia and anemia was rare. In this study, treatment response was evaluated by CT at one or two months after TACE, and was considered separately as “parenchymal-response” and “PVTT-response”. Mean survival times were 11.1 mo vs 5.5 mo for parenchymal response positive patients compared to negative ones, and 14.0 mo vs 5.8 mo for PVTT response positive patients compared to negative ones.

TACE efficacy in the treatment of PVTT seems to be related to the degree of hepatic arterial supply to the thrombus. Indeed, patients showing a good accumulation of lipiodol after TACE presented a better response to TACE, with an OS of 10 mo vs 2.7 mo (P < 0.001)\cite{69}.

When TACE is compared to sorafenib in BCLC-C HCC, the median OS seems to be similar (9.2 mo vs 7.4 mo; P = 0.327) but the incidence of AEs appears to be higher in the TACE group (30\% vs 17\%)\cite{70}.
| First author, year | Patients (patients) | Treatment | PVTT Class (Vp) | Median survival time (mo) | 1-yr survival rate | 2-yr survival rate | 3-yr survival rate | 5-yr survival rate |
|-------------------|--------------------|-----------|----------------|--------------------------|------------------|------------------|------------------|------------------|
| Okazaki M, 1991   | 163                | TACE      | Vp 2 (48) Vp 3 (56) Vp 4 (59) | 4.3 mo 4 mo 3.8 mo | -                | -                | -                | -                |
| Chung JW, 1995    | 83                 | TACE      | Vp 3,4 (83) | 6 mo                    | 30%              | 18%              | 9%               | -                |
| Georgiades CS, 2005 | 32             | TACE      | Vp 3,4 (32) | 9.5 mo                  | 25%              | -                | -                | -                |
| Luo J, 2011       | 84                 | TACE      | Vp 1,2 (40) Vp 3 (44) | 10.2 mo 5.3 mo    | 30.9% 3.8%       | 9.2% 0%          | -                | -                |
| Niu ZJ, 2012      | 115                | TACE      | Vp 1 (12) Vp 2 (52) Vp 3 (42) Vp 4 (9) | 19 11 7.1 4 | 27.8%            | 6%               | -                | -                |
| Peng ZW, 2012     | 402                | TACE      | Vp 1 (54) Vp 2 (136) Vp 3 (166) Vp 4 (46) | - | 41.1% 37.9%      | 36.1% 30.4%      | 4.3%             | 3.6% 0% 0% 0%    |
| Ajit Y, 2014      | 188                | TACE      | Vp 1,2 (98) Vp 3 (90) | 6.2 mo                | -                | 22%              | -                | -                |
| Liu L, 2014       | 181                | TACE      | Vp 1,2,3,4 | 6.2 mo (range, 1.7–50.9 mo) | 22%             | 10%              | 8%               | -                |
| Liu PH, 2014      | 50                 | TACE      | Vp 1,2,3,4 | NA                      | 45%             | 23%              | 20%              | -                |
| Chern MC, 2014    | 81                 | TACE      | Vp 1,2,3,4 | Vp 2,3 (64 patients) TACE+PVE (52 patients) | 7.0 mo            | 17.5%            | 0%               | 0%               |
| Ye JZ, 2014       | 338                | TACE      | Vp 1,2,3,4 | Type I, II, III (according to Shi et al) | 27.7 mo          | 60.9% 80.7%      | 41% 59%          | 25% 36.5% 0%     |

The combination of sorafenib and TACE is reasonable considering their complementary effects: On one side, TACE determines hypoxia that could enhance the release of angiogenic factors; on the other side, sorafenib has an antiangiogenic activity (anti-VEGF-2 and 3, anti-PDGF Receptor) and suppresses tumour proliferation\[71\]. A metanalysis by Liu et al\[72\], examining 17 studies on the combination of sorafenib and TACE in unresectable HCC compared to TACE alone, showed benefits in TTP but not in OS (TTP: 7.1–9.0 mo; OS: 12–27 mo). AEs were mainly grade 1-2 (alopecia, fatigue, nausea, diarrhoea, HFSR, haematological events, hepatotoxicity) and manageable with sorafenib dose-reduction. Heavy limitations of this analysis were represented by the wide heterogeneity of accessible data, and lack of OS and TTP in non-comparative studies that were, however, included. Furthermore, the phase II trial START performed in Asia and assessing the effectiveness of the combination of TACE with Sorafenib showed promising results in PVTT patients in terms of 3-year OS (86.1%) with acceptable rates of AEs\[73\].

A retrospective study by Kim et al\[74\] demonstrated better OS and longer TTP for patients treated with the combination of TACE and RFA than with TACE or sorafenib alone.

Zhang et al\[75\] observed an improved outcome applying percutaneous transhepatic portal vein stenting (PTPVS) and TACE, with or without 3-dimensional conformal radiotherapy (3-DCRT): Median OS was 16.5 mo in the radiotherapy (RT) group vs 4.8 in the non-RT one. This study also demonstrates better results of PTPVS-TACE with 3-DCRT especially in avoiding stent re-oclusion due to tumour thrombus regrowth.

On the whole, TACE alone improves survival of selected patients with unresectable HCC, but its effectiveness in improving OS and TTP of PVTT patients is not definitively proven\[76\]. The association of TACE to other treatments could provide an additional benefit by improving local control of HCC growth but further data are needed in order to demonstrate a positive influence on OS.

**RT**

HCC is a radio-resistant carcinoma, but, in selected patients with PVTT, RT was
demonstrated to be effective with a dose-related response\cite{77,78}. However, RT can lead to severe liver damage\cite{79}. Indeed, concerns exist upon a “veno-occlusive-disease-mimicking” radiation-induced liver disease (RILD) characterized by jaundice, severe hypertransaminasemia, hepatomegaly and ascites appearing 2-3 mo after RT. This threatening condition still remains without specific treatments and its prognosis is potentially negative\cite{80}. However, a small volume of liver tissue could tolerate potentially tumoricidal high radiation doses. Indeed, Lawrence et al\cite{81} demonstrated that the use of dose-volume histogram allows to concentrate a higher radiation dose on neoplastic tissue while sparing 2/3 of normal hepatic tissue, producing response rates 2-3 times higher faced to conventional therapy, thus obtaining a better local disease-control) and new technologies allow to achieve a highly selective target receiving high doses radiation and sparing normal tissue, thus avoiding RILD\cite{82,83}.

Some attempts to make this technique more selective and tolerable were made through the use of 3-DCRT which allows to apply radiation selectively on both tumor mass and PVTT and to avoid irradiation on the surrounding hepatic and non-hepatic tissues\cite{84}.

Tang et al\cite{85} compared RT to surgery in a retrospective study on 371 patients with resectable HCC and PVTT obtaining better outcomes for the RT arm: Median OS was 12.3 mo vs 10 mo, respectively; 1-, 2-, and 3-year OS was 51.6%, 28.4%, 19.9% for the RT group and 40.1%, 17.0%, 13.6% for the surgery group (P = 0.029). Other studies on Vp3-4 PVTT showed a survival rate of 5.3-7 mo, with response rates ranging between 32.6% and 83%\cite{86,87,88}.

A study by Nakazawa et al\cite{89} comparing RT to placebo on high grade PVTT (Vp3-4, Vv2-3), showed a 48% overall objective response rate (complete plus partial response): 56% for Vp, 50% for Vv, 20% for both Vp and Vv). Median survival time in patients receiving RT was 10 mo vs 3.6 mo in the control group; furthermore, 1- and 2-year cumulative survival rates were significantly higher (38% and 20.7% vs 8.3% and 2.7%).

No grade 3 AEs occurred; the most common AEs were fatigue, anorexia, leukopenia and hypertransaminasemia of grade 1 or 2.

A recent study performed using the propensity score matching highlighted the superiority of RT vs sorafenib in patients with Vp3-4 PVTT (OS 10.9 mo vs 4.8 mo; P = 0.025); complete regression was achieved in 3.6% patients, partial response in 50.2% and stable disease in 25.6% in the RT arm. Serious AEs were more frequent in the sorafenib group (hypertransaminasemia, anorexia, nausea, HFSR), while only one case of grade 3 leukopenia occurred in patients undergoing RT\cite{90}.

Positive results have also been reported on proton-beam therapy (PBT) in HCC with PVTT, because of the possibility to locally concentrate the radiation delivery. In a study by Sugahara et al\cite{91} the median OS was 22 mo, with 91% 2-year local control rate and 48% 2-year survival rate; only a few patients presented grade 3 AEs, mainly consisting in leukocytopenia and thrombocytopenia. In another study 12 patients with Vp3-4 PVTT were studied after PBT: 2 of them obtained a complete response without recurrence 4.3 and 6.4 years after treatment. The remaining 10 showed partial response 1-3 mo after PBT (objective response rate 100%), with appearance of new HCC outside the irradiated volume after further 0.1-2.4 years from PBT. PFS and OS rates were 67%/24% and 88%/58% at 2 and 5 years, respectively. No grade 3 AEs were observed\cite{92}.

Several RT techniques (3-DCRT, intensity-modulated RT, stereotactic body RT (SBRT), and RT with proton beams and carbon ion beams) showed promising outcomes in HCC patients with and without PVTT: PBT, unlike RT with X-rays, allow to precisely deliver high-dose radiations to the target volume, sparing the normal liver tissue and the surrounding organs\cite{93,94}. Furthermore, a metaanalysis by Qi et al\cite{95} demonstrated a higher rate of survival for PBT compared to CRT, with lower AEs.

Gamma knife radiosurgery (GKR) is a type of external radiation treatment applied especially on brain lesions, focusing with gamma beams radiations precisely on the target, thus avoiding damage to surrounding healthy brain tissue. It consists in a single application whereas RT requires multiple sessions to attenuate the effects of radiation on healthy tissues. In a few Chinese centers, GKR has been applied on HCC-PVTT for more than a decade. A retrospective study by Lu et al\cite{96} identified a remarkably increased median OS of HCC-PVTT patients receiving combined TACE and GKR faced to TACE alone. A subsequent retrospective study by Lu et al\cite{97} investigated the efficacy and safety of GKR monotherapy on PVTT-HCC, highlighting an OS advantage in both patients with branch or main PVTT (6.1 mo for GKR group vs 3.0 mo for supportive therapy)\cite{98,99}. Grade 1-2 AEs were predominant and easily managed. Despite the need of further future validation, GKR was reported to be effective on HCC with PVTT, without differences related to its extension\cite{97}.

The combination of RT with other treatment modalities represents also an interesting approach. For example, TACE determines the necrosis of the tumor thrombus by reducing the arterial supply and stimulates G0 cells to enter into the
Cerrito L et al. Treatment of HCC with PVTT

Treatment of HCC with PVTT

Hepatocellular carcinoma – SARAH studies, two phase III trials (Sorafenib versus Radioembolization [112-115] superior to sorafenib in prolonging survival of PVTT patients in some retrospective. Furthermore, although TARE was reported to be median survival time than TARE [111]. In a recent paper, Spreafico seems to favor sorafenib in term of OS.

The benefit of TARE could be better. In a recent paper, Spreafico et al [116,117] versus Sorafenib – [116,117] studies. In [119] study [119], combined treatment with RFA and TACE on HCC complicated by PVTT and main portal trunk recanalization was achieved in 26 patients (74%). In another patients with main trunk PVTT, the 3-year survival rate was 97.7% (because of advanced HCC, liver failure, HCC-rupture) while the others survived more than 6 mo. Further studies also reached satisfying response rates [9,18-103].

Another study claimed the superiority of surgery plus neoadjuvant RT over surgery alone in preventing tumor recurrence (1-year OS 69.0% vs 35.6%, 2-year OS 20.4% vs 0%, 6-mo RR 49.0% vs 88.7%, 1-year RR 77.0% vs 97.7%) [116].

Finally, Nakagawa et al [109] demonstrated the relevant role of RT followed by percutaneous ethanol injection (PEI), RFA or TACE in HCC with Vp2-4 PVTT, with a 50% response rate and 1-, 3- and 5-year survival rate of 45.1%, 15.2% and 5.1% respectively. Table 2 summarizes the most important papers analyzing the effectiveness of RT alone or associated with other treatments in PVTT.

Transarterial radioembolization (TARE) acts by delivering local beta radiation within HCC through the selective release of iodine-131-labeled lipiodol (131I), iodine (131I) or yttrium (90Y) in lobar, segmental, or subsegmental hepatic arteries supplying the tumor [9,103]. In contrast to TACE, for which PVTT is a technical issue and an absolute contraindication in case of Vp3-4 stage due to the increased risk of liver ischemic necrosis and treatment-related death, TARE can be performed in patients with PVTT without major concerns, thanks to the minimal embolic effect of 90Y-glass microspheres and consequent lower risk of liver ischemia [104].

In a small study on 32 patients, Shae et al [109] compared the effects of TARE and TACE in a subgroup of patients with major vascular invasion, obtaining a median survival of 12 mo vs 9 mo (3-year survival rate 20.3% vs 9.7%).

TARE has also been shown to be more tolerable than TACE or Sorafenib: The most frequent AE, observed in 20-55% of patients, is post-embolization syndrome (fever, nausea, abdominal pain, malaise), which does not require medical intervention in most cases [110]. However, in a retrospective, multicentre, therapy registry, doxorubicin drug eluting beads (DEBDOX) resulted to be safer in the treatment of unresectable HCC with PVTT, achieving better disease control (67% vs 20%;  P = 0.0014) and median survival time than TARE [111]. Furthermore, although TARE was reported to be superior to sorafenib in prolonging survival of PVTT patients in some retrospective studies [112-113], two phase III trials (Sorafenib versus Radioembolization in Advanced Hepatocellular carcinoma – SARAH – and Selective Internal Radiation Therapy Versus Sorafenib – SIRveNIB) [115,117] failed to demonstrate a significant superiority of TARE compared to sorafenib. In particular, in the SARAH study the presence of PVTT seems to favor sorafenib in term of OS.

An interesting point could be the selection of a subgroup of PVTT patients in whom the benefit of TARE could be better. In a recent paper, Spreafico et al [109] developed a prognostic classification showing that patients with at least one measurable HCC lesion, PVTT non-occluding the main portal vein, absence of extra-hepatic metastasis, Child-Pugh < B7, and good performance status achieved the best therapeutic results.

Percutaneous ablation therapies

Percutaneous treatments have been proposed for HCC complicated by PVTT, but particular caution must be paid because of the potential risk of damaging portal and biliary structures. However, some preliminary attempts have been done, with discrete results.

In a study planned in 2005 when sorafenib was not available and including 35 patients with main trunk PVTT and a single HCC nodule (size 3.7-5 cm) who underwent RFA of both the HCC lesion and PVTT, the 3-year survival rate was significantly higher when compared to no treatment (77% vs 0%) [111], with a mean survival time of 28.3 ± 3.8 mo vs 6.8 ± 5.0 mo (P < 0.001). A complete tumor necrosis and main portal trunk recanalization was achieved in 26 patients (74%). In another study [119], combined treatment with RFA and TACE on HCC complicated by PVTT was reported to achieve a mean survival time of 29.5 months, with a 1-, 3-, 5-year...
Table 2 Main studies on the outcome of radiotherapy alone or combined with other treatments in patients with hepatocellular carcinoma and different portal vein tumor thrombosis grades

| First author, year | Patients (patients) | Treatment | PVTT Class (Vp) | Response rate | Survival rate(yr) | Mean survival time(mo) |
|-------------------|---------------------|-----------|-----------------|---------------|------------------|-----------------------|
| Tazawa, 2001      | 24                  | RT (50 Gy)+TACE | Vp3,4          | 50%           | NA               | 9.7 mo                |
| Yamada, 2001      | 8                   | RT (30 Gy)    | Vp3             | 37.5%         | NA               | NA                    |
| Ishikura, 2002    | 20                  | TACE+RT (50 Gy) | Vp3           | 50%           | 25% (1-yr)       | 5.3 mo                |
| Yamada K, 2003    | 19                  | TACE and 3D-RT (30Gy) | Vp3      | 57.9%         | 40.6% (1-yr), 10.2% (2-yr) | 7 mo |
| Nakagawa, 2005    | 52                  | 3D-CRT (39-60 Gy) | Vp2,3,4       | NA            | 5.1% (5-yr)      | NA                    |
| Kim DY, 2005      | 59                  | 3D-CRT (39-70.2 Gy) | Vp3,4       | 45.8%         | 20.7% (2-yr)     | 10.7 mo               |
| Hata, 2005        | 12                  | Proton-beam therapy (50-72 Gy) | Vp3,4 | 100%         | 88% (2-yr) 58% (5-yr) | 27 mo |
| Lin CS, 2006      | 43                  | 3D-CRT (21patients) Conventional Rtp (22 patients) | Vp3,4 | 83% 75%     | NA NA             | 6.7 mo 6.0 mo |
| Hsu WC, 2006      | 53                  | 3D-CRT+thalidomide | Vp3,4        | 50%           | 84.8% (6mo), 60.0% (1-yr), 44.6% (2-yr) | 24.0 mo |
| Nakazawa, 2007    | 32                  | RT          | Vp3,4, Vv2-3   | 48%           | 38.0% (1-yr), 20.7% (2-yr) | 10.0 mo |
| Toya, 2007        | 38                  | 3D-CRT (23.4-59.5 Gy) | Vp NA       | 44.7%         | 39.4% (1-yr)     | 9.6 mo (OS)           |
| Shirai, 2009      | 26                  | 3D-CRT using SPECT | Vp3,4      | 30.7%         | 30% (2-yr)       | 10.3 mo               |
| Kang, 2013        | 101                 | RT+TACE TACE+RT | Vp NA        | 70.3%         | A) 58.8% (1-yr), 29.4% (2-yr) B) 54.1% (1-yr), 27.0% (2-yr) | 17 mo 15 mo |
| Nakazawa, 2014    | 97                  | 3D-CRT (30-56 Gy) | Vp3,4        | 45%           | NA               | 10.9 mo               |
| Lee, 2014         | 46                  | 3D-CRT (35-60 Gy) | Vp3,4        | 32.6%         | 66.8% (1-yr)     | NA                   |

3D-CRT: Conformal radiotherapy; Gy: Gray; NA: Not available; PVE: Portal vein embolization; PVTT: Portal vein tumor thrombosis; RT: Radiotherapy; SPECT: single photon emission computed tomography; TACE: Transarterial chemoembolization.

Survival rate of 63%, 40% and 23%. Slightly inferior rates were obtained when using laser as ablation technique[30].

Cryotherapy has also been considered as a complementary treatment to sorafenib in patients with branch and main-trunk PVTT, with a significant increase in OS (12.5 mo vs 8.6 mo respectively) and good safety profiles[31].

The main limitation of ablation techniques is the extension and the location of PVTT within the portal system. Indeed, severe side effects such as neoplastic embolization, irreversible damages of vascular and biliary structures, gallbladder, gastric and duodenal walls have been occasionally reported after PVTT ablation using percutaneous ethanol injection, RFA or laser[41,120,122]. Electrochemotherapy (ECT) is an innovative method based on local application of short and intense electric pulses that temporarily permeabilize cellular membranes, permitting the delivery of therapeutic molecules. It has been used in a small prospective case series of HCC patients with Child-Pugh A-B liver cirrhosis and Vp3-4 PVTT: Post-treatment CEUS examination and biopsy of the portal thrombus showed in all cases a complete necrosis of tumor cells without involution signs in perivascular tissues and portal endothelium. During the subsequent 12-mo follow-up, no local recurrence was detected. The main concern on this promising technique is the occurrence of thrombosis of main portal trunk and fatal late gastrointestinal haemorrhage (17% of treated patients)[123].

**Surgical approach**

Since 1980s, surgical resection has been adopted for the treatment of HCC with PVTT of the first-order branches[124]. In 1990s, Kumada et al[125] reported a surgical resection of a tumor thrombus extended in the main portal trunk, describing five possible surgical approaches: (1) Hepatolobectomy, consisting in the en-bloc resection of both HCC (located either in the left or the right lobe) and PVTT (confined to the first portal branch); (2) Thrombectomy with a balloon catheter that is introduced in the clamped portal vein by an incision and used to extract the thrombus by suction or curettage; (3) Portal vein bypass, consisting in the en-bloc resection of both the involved portal branches and the thrombus when its extraction is technically complicated, followed
by the creation of a bypass-graft between portal trunk and umbilical vein; (4) Portal vein resection and anastomosis, performed in the presence of PVTT of the contralateral first branch, with an en-bloc resection of both the thrombus and the portal trunk, and the subsequent anastomosis between portal trunk and the residue of portal vein; (5) Thrombectomy, with the extraction of the thrombus through an incision in portal wall at the bifurcation of right or left vein, while a biologic pump redirects portal and vena cava blood flow to the axillary vein; if PVTT removal is difficult, portal vein should be resected and subsequently reconstructed.

Nowadays, surgical approach to PVTT is based on three main methods: Hepatectomy, tumor thrombectomy, and en-bloc-resection of portal vein and thrombus with subsequent portal reconstruction. The first one represents an excellent solution in case of PVTT in the first portal branches in patients with satisfying clinical condition, as it grants a radical tumor and PVTT removal. The second one has the potential advantage of avoiding tumor residuals, but it is technically more difficult to perform, especially in case of extended thrombosis. The latter, applied to PVTT involving the bifurcation with or without the main and/or contralateral portal veins, presents high intraoperative mortality risk, but a more favorable result faced to thrombectomy that is technically less difficult, but with a higher risk of tumor residual or metastatization to the distal branches. A study by Chok et al. compared these three surgical methods (hepatectomy, tumor thrombectomy, and en-bloc-resection of portal vein and thrombus), highlighting that median disease-free survival was 4.21, 1.51 and 3.78 mo, respectively. This implies that adjuvant treatments would be necessary to prevent the high incidence of recurrence but, unfortunately, they are still unavailable.

It should be noted that no prospective study on surgical treatment for PVTT is available to date. Some studies underlined the achievement of the same survival and disease-free survival outcomes for en-bloc resection of the involved liver segment and bifurcation with or without the main portal trunk compared to thrombectomy with peeling-off technique. Conversely, a propensity score analysis by Zhang et al. demonstrated the superiority of en-bloc resection compared to thrombectomy with peeling-off resection in type I-II PVTT (mean survival time, MST 18.2 mo vs 10.9 mo, 1-, 3-, 5-year OS 68.9%, 34.3%, 30.8% vs 49.1%, 22.1%, 15.8%; recurrence rate 9.7% vs 23.9%, P = 0.005, respectively).

Back-flow thrombectomy (BFT) has been employed in order to expand therapeutic possibilities for Vp4 PVTT, which in Japan is surgically approached only in 8.8% cases, minimizing the risk of migration of floating thrombus and allowing further adjuvant treatments.

Beyond its pathological meaning and the debates on the most proper therapeutic approach, PVTT itself has a fundamental role in defining the possible evolution of HCC. In patients with HBV-related HCC macrovascular invasion, tumor differentiation and size are all important prognostic factors. As regards surgical resection of large HCC (more than 10 cm), PVTT is an independent predictor of early recurrence-related mortality and a major negative prognostic factor. Since PVTT invading portal trunk is considered to be a sign of advanced HCC, the purpose of surgical approach is not to improve survival, but to help preventing the consequences of excessively high portal pressure (e.g., variceal hemorrhage). However, even in patients with PVTT of the portal trunk, a slight improvement of survival has been reported even when compared to treatment with sorafenib. A review of 24 studies including 4389 patients with PVTT undergoing surgical resection, evidenced a 1-year OS of 50% and 5-year OS of 18%. Peng et al. showed a 1-, 3- and 5-years survival rate for type I and II PVTT of 42%, 14.1%, 11.1% for surgery and 37.8%, 7.3%, 0.5% for TACE, respectively; however, the size of the surgery group was about half of the TACE group (201 vs 402), and the subgroups analysis presented statistically significant results only in type I and II PVTT (P < 0.001 and 0.002), but not in type III and IV (P = 0.541 and 0.371); R0 resection could be achieved in 83% patients (88/106) with HCC and PVTT but no vascular wall invasion, as already indicated by Shi et al. who suggested thrombectomy as a proper treatment option if the tumor thrombus does not infiltrate portal venous wall. Further studies confirmed the superiority of surgery over TACE, especially in type I and II PVTT.

Liver resection and thrombectomy have a better 5-year OS if the PVTT is confined to the first or second branch of the main portal vein rather than to portal trunk. A review analyzing 23 articles and 2412 patients noticed a substantial difference in 5-year post-resection survival related to PVTT stage: Vp1-2 45% (range: 25%-54%), Vp3 19% (range: 0%-38%), Vp4 14.5% (range: 0%-26.4%). Wang et al. suggested that, beyond type I and II PVTT (according to Chang’s classification), surgery could be effective also in selected cases of type III PVTT. Indeed, surgery allows an en-bloc removal of neoplastic tissue in type I and II but in type III it is mandatory to clamp portal vein, perform a thrombectomy and subsequent washing of the vascular lumen.
with saline solution, in order to remove possible neoplastic residuals.

At present, neither precise consensus nor indications have been established for each Vp-category: According to LCSGJ, Vp1-3 are candidate to resection, but Vp4 has a weak indication; taking into account Cheng’s classification, type I-III could be treated by surgery, while type IV represents a contraindication. A study by Sakamoto et al.\cite{125} proposed for Vp4 PVTT an en-bloc resection with reconstruction of the portal vein or thrombectomy. Another Japanese group\cite{155} underlined that only Vp3 may have benefits from surgery, while Vp4 should be treated with alternative therapies.

Yamamoto et al.\cite{150,151} claimed that hepatectomy provides comparable survival rates for both Vp3-4 and Vp1-2 but in this series Vp3-4 group is really small faced to the Vp1-2 group. They also suggested that stage II-III patients [according to American Joint Committee on Cancer (AJCC)] with high serum alpha-fetoprotein levels should undergo neoadjuvant/adjuvant therapies.

A retrospective multicenter analysis of liver resection associated to thrombectomy performed in Italy did not report a significant difference of 5-year survival among Vp1, Vp2 and Vp3 patients\cite{158,160-164}. Roayaie et al.\cite{166} reported a MST of 13.1 mo and 14% 5-year survival in patients with PVTT treated with resection, whereas in case of involvement of hepatic veins and vena cava MSTs felt to 4.7 mo. In case of HCC < 7 cm and AFP < 30 ng/mL, MST was 20 and 29 mo respectively. Prognostic elements such as tumor size, extension of vascular invasion and AFP resulted to be fundamental to define the outcome and should be considered when deciding if resection is possible. The main studies concerning the clinical outcome of patients with HCC and PVTT are reported in Table 3.

A metanalysis by Hyun et al.\cite{167}, examining 5986 patients from 18 studies, showed that primary hepatectomy is superior to TACE in BCLC-B/C stage HCC, with significant OS benefit (HR = 0.59; 95%CI: 0.51-0.67; P < 0.00001); as per BCLC-B, also in BCLC-C group, 1-, 3-, 5-years survival rates were higher for primary hepatectomy than TACE (62%, 42%, 20% vs 56%, 32%, 14%, respectively). Despite these intriguing results, the long-term effectiveness of surgery in advanced HCC is still to be proven, since no comparison was made between surgery versus standard systemic treatment with sorafenib in this group of patients. Zhang et al.\cite{153,154} proposed the preoperative Eastern Hepatobiliary Surgery Hospital (EHBH) PVTT scoring system predicting accurately the prognosis after R0 LR of HCC patients with type I-II PVTT: This method could facilitate the decision between conventional systemic treatment and surgery in patients with advanced HCC because of its accuracy in selecting patients who could be advantaged by LR.

Associated Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS) is an innovative surgical technique, first developed in 2012, for the management of liver metastases in patients with potentially small residual liver volume, that reduces the time of liver hypertrophy from 4-6 wk (in case of standard portal embolization) to 7-10 d. It consists of in situ splitting of the liver along the main portal scissura or the right side of the falciform ligament, associated with right portal vein ligation\cite{157}: Vennarecci et al.\cite{158} demonstrated its efficacy in two cases of HCCs with major vascular invasion in which the classical approach of radiological or surgical portal-vein occlusion and subsequent resection after 4-6 wk could not be performed; these patients were still alive 7 and 12 mo after surgery.

**Surgery combined with other treatment methods**

A combination strategy involving surgery has been reported to be more beneficial than surgery alone\cite{160}. However, the available data are still fragmentary and involve a limited number of cases. Then, further prospective randomized clinical trials are needed to achieve solid conclusions.

TACE following resection has been associated to a reduction in disease-recurrence and a prolongation of OS. This effect is obtained especially in patients with high-recurrence-risk such as those with large tumors and vascular invasion\cite{156,157}. Neoadjuvant RT can achieve tumor downstaging allowing surgery and improving disease-free and OS without significant radio-mediated liver-damage\cite{166}. In particular, PVTT seems to have a better radio-sensitivity than HCC itself (response rate 27% vs 13% respectively): This allows to reduce the duration of the intervention, the bleeding-risk and the possibility of micrometastatization by small thrombotic fragments during surgery\cite{150,151}. Kamiyama et al.\cite{165} described the possible role of RT as neoadjuvant treatment before surgery in patients with Vp3-4 PVTT, helping to improve prognosis through the inactivation of thrombus tumor cells and consequent prevention of dissemination, with a mean survival time of 19.6 mo. Some studies also proved TARE with yttrium-90 to be effective in downstaging unresectable HCC with PVTT, increasing patients’ survival\cite{156,157}.

Sorafenib has been tested as adjuvant therapy to prevent recurrence after surgical intervention. However, the initial promising results on animal models\cite{167}, were not
Table 3 Selected studies concerning the outcome of resective surgery in patients with hepatocellular carcinoma and different portal vein tumor thrombosis grades

| First author, year | Patients (patients) | PVTT Class (Vp) | Mortality | 5-yr survival rate | Median survival time (mo) |
|--------------------|---------------------|-----------------|-----------|--------------------|--------------------------|
| Yamaoka, 1992      | 29                  | 3-4             | 11%       | 11.6% (3-yr)       | NA                       |
| Ikai, 1998         | 26                  | 3               | NA        | 11% 4%             | NA                       |
| Ohkubo, 2000       | 47                  | 2-3-4           | 0%        | 23.9              | 14 mo                    |
| Wu, 2000           | 97 15               | 1-2-3-4         | 3.1% 0%   | 28.5 26.4%        | NA NA                    |
| Poon, 2003         | 20                  | 3-4, Vv2        | 5.7%      | 13.3              | 6.0 mo                   |
| Ikai et al, 2004   | 17,867 1609 672 679 | 0 1 2 3-4       | NA        | 56.5 34.4 27.0%   | 17.3                     |
| Pawlik, 2005       | 102                 | 3, Vv 2-3      | 5.9%      | 10% 11 mo         | 11 mo                    |
| Ikai, 2006         | 78                  | 3-4             | 3.8%      | 10.9% 8.9%        | 10.1 mo                  |
| Chen, 2007         | 286 152             | 1-3-4           | NA 2.6%   | 18.1 0%           | 10.1 mo                  |
| Le Treut, 2006     | 26                  | 3-4, Vv2-3     | 11.5%     | 13% 9.0 mo        |                          |
| Zhou, 2006         | 381                 | 2-3-4           | NA        | 12%               | NA                       |
| Shi, 2011          | 144 189 86 22       | 1 2 3 4        | NA        | 26.7% (3-yr) 16.9% (3-yr) 3.7% (3-yr) 0% (3-yr) | NA                       |
| Inoue et al, 2009  | 20                  | 4               | 0%        | 39.0%             | NA                       |
| Ban, 2009          | 45                  | 3-4             | 0% 0%     | 41.8% 20.9%       | 20.0 mo                  |
| Kondo, 2009        | 5                   | 4               | 0%        | 0% 8.0 mo         |                          |
| Ikai et al, 2010   | 20,195 1978 820 1,021 | 0 1 2 3-4    | NA        | 59.0% 39.1% 23.3% | 18.3%                    |
| Shi, 2010          | 169 78              | 3-4             | 0.6% 0%   | 17.7% (3-yr) 3.6% (3-yr) 15.0 mo 10.0 mo |                          |
| Wang, 2013         | 25                  | Vv3             | 0%        | 13.5%             | NA                       |
| Chok, 2013         | 88                  | 1-2-3-4         | 3.3%      | 11.2-14.3%        | NA                       |
| Pesi, 2015         | 15 5 21 8 3         | 1 2 3 Vv2 Vv3  | NA        | 53.3% 30.1% 20.0% NA |                          |
| Xu, 2015           | 16 40               | A B             | 100% NA   | 0% 5.2%           | NA                       |
| Kokudo, 2016       | 1772 1475 1942 1285 | 1 2 3 4       | NA        | 2.67 yr 1.51 yr 0.78 yr 0.50 yr |                          |
| Kudo, 2016         | 1908 714 852        | 1 2 3-4         | NA        | 48.2% 29.2% 25.05 | NA                       |

NA: Not available; PVTT: Portal vein tumor thrombosis.

confirmed in humans. An increased overall survival was reported in animal models and in a small series of 12 patients with HCC in the BCLC-C stage treated with sorafenib after resection faced to the 24 ones treated with surgery alone[168].

Tang et al[169] reported that combination of surgery plus chemotherapy is effective for HCC with PVTT, increasing survival rates faced to other therapeutic strategies (chemotherapy alone, surgery alone, conservative treatment). Remarkable data were also obtained comparing hepatectomy plus thrombectomy to heptectomy plus thrombectomy plus chemotherapy (1-year and 3-years survival rates of 47% vs 70% and of 22% vs 20%, respectively)[5]. Nagano et al[170] also showed a 100% overall 1-year survival using subcutaneous IFN-alpha and hepatic arterial infusion of 5-FU after palliative resection of advanced HCC with PVTT.

However, none of these studies clearly demonstrates that chemotherapy increases PVTT outcome after surgery.

LT

According to international guidelines, HCC with PVTT still remains a contraindication for LT because of the elevated risk of tumor recurrence, but also because of technical difficulties and post-operative mortality[59,171-174].

However, based upon the positive experiences with living-donor LT after successful downstaging, the role of PVTT as an absolute contraindication to LT deserves a reconsideration. A recent study reported on the use a pre-waiting list LT protocol of intensive downstaging treatment in a living donor LT program based on concurrent chemoradiotherapy (CCRT) followed by HAIC[175]. Patients achieving successful downstaging underwent LT and median patient and graft survival was 33
months. Some important issues emerged from this study: Technical limitations due to anatomic modifications determined by downstaging treatments, the prognostic value of biomarkers (e.g., AFP, PIVKA-II – protein induced by vitamin K absence or antagonist-II), the high recurrence rate (3/8 patients).

An interesting study by Levi Sandri et al. showed encouraging results of TARE for PVTT-HCC downstaging prior to LT in four patients; DFS was 39.1 mo and in all cases complete thrombosis regression was achieved, demonstrating the potential role of TARE in tumour downstaging for LT candidates. These data underline the importance of TARE as a useful downstaging tool for PVTT-HCC opening a possible scenario for LT.

External radiation therapy has also been considered for PVTT as a bridging or downstaging therapy. A small retrospective series of 10 patients receiving hypofractionated image-guided RT (HIGRT) followed by LT, presented pathologic complete response in 27% of cases; in the others, the lesions were decreased or stable in size. Five years after LT all patients were alive and no recurrence was observed. In another study on 38 patients treated with HIGRT and LT, complete plus partial pathologic response was achieved in 68%.

HCC patients with PVTT treated with resection, TACE and LT present an increased survival rate compared to those receiving conservative treatment (30% vs 12% at 1 year and 10% vs 4% at 3 years).

All these experiences contribute to endorse downstaging strategies as an essential preliminary condition to allow PVTT-HCC to undergo LT without an excessively consistent risk of recurrence.

**CONCLUSION**

Patients with HCC and PVTT still remain a subgroup with poor survival, despite the efforts to expand treatment indications outside the BCLC algorithm. The most evident survival advantages can be attributed to surgery and several centers are moving towards an extension of BCLC indications in these patients. Recently released guidelines by European Association for the Study of the Liver (EASL) and American Association for the Study of Liver Diseases (AASLD) reflect this new tendency and the favourable results reported by both Eastern and Western surgical groups for patients with PVTT of the first/secondary branches (Vp1/2), support the differentiation of treatment algorithms according to PVTT extension.

The importance of the scientific debate on PVTT treatment is summarized by Wang et al. who focus on the exiguous survival advantage offered by palliative therapies (such as sorafenib) confronted with their high health-costs. A revision of western countries guidelines is required to fully recognize hepatic resection as a valid alternative for selected cases of advanced HCC. The reason why this strategy is not yet applied probably resides in the low incidence of HCC in Western countries compared with Eastern ones and the coexistence in developed countries of several comorbidities, such as cirrhosis, resulting in the risk of poor OS after resection, thus leading either to conservative surgical strategies or to merely palliative therapies. Despite these concerns, a study by Kokudo et al. reported a less than 4% postoperative 90-day mortality for hepatic resection in PVTT-HCC. For this reason, notwithstanding obvious technical difficulties of surgery in complex patients (e.g., cirrhotic, cardiopathic ones), it should be given a larger space as a therapeutic option in patients with first-order branch PVTT and normal liver function, because of its safety and efficacy. For those with PVTT in main trunk or contralateral branches, TARE and sorafenib (alone or combined) represent the most suitable solution.

There is still a deep gap of knowledge in the field of HCC associated with PVTT as only preliminary and insufficient data are available on the effectiveness of combining neoadjuvant treatment with resection and no prospective study comparing surgery with other treatments has been reported. In the meanwhile, the involvement of a multidisciplinary tumor board is mandatory in order to provide the best therapeutic decision for complex, selected cases, considering risks and benefits in the light of residual liver function which remains a decisive factor in the orientation of therapeutic choices.

Although sorafenib represents at the present time the only recommended approach in this category of patients, it is important to remind that, for selected cases, alternative therapeutic approaches with a good safety and effectiveness profile such as surgery and TARE are available, and that the sequential and personalized combination of different treatment modalities will probably lead in the future to a deep modification of BCLC treatment pathways.
REFERENCES

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; 136: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]

2. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. *Hepatology* 2008; 48: 137-145 [PMID: 18537177 DOI: 10.1002/hep.22312]

3. Colombio M, de Franchis R, Del Nimo E, Sangiovanni A, De Fazio C, Tommasini M, Donato MF, Piva A, Di Carlo V, Dioguardi N. Hepatocellular carcinoma in Italian patients with cirrhosis. *N Engl J Med* 1991; 325: 675-680 [PMID: 1651452 DOI: 10.1056/NEJM199101303250603]

4. Manzano-Robleda Mdel C, Barranco-Fragoso B, Uribe M, Méndez-Sánchez N. Portal vein thrombosis: what is new? *Ann Hepatol* 2015; 14: 20-27 [PMID: 25536638]

5. Minagawa M, Makuuchi M, Takayama T, Ohtomo K. Selection criteria for hepatocarcinoma in patients with hepatocellular carcinoma and portal vein tumor thrombus. *Ann Surg* 2001; 233: 379-384 [PMID: 11224626 DOI: 10.1097/00000655-200103000-00012]

6. Zhou Q, Wang Y, Zhou X, Peng B, Yang J, Liang L, Li J. Prognostic analysis for treatment modalities in hepatocellular carcinomas with portal vein tumor thrombi. *Asian Pac J Cancer Prev* 2011; 12: 2847-2850 [PMID: 22393052]

7. Piscaglia F, Gianstefani A, Ravaioli M, Golfieri R, Cappelli A, Giampalma E, Sagnini E, Imbrago G, Pinna AD, Bolondi L. Bologna Liver Transplant Group. Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. *Liver Transpl* 2010; 16: 658-667 [PMID: 20407775 DOI: 10.1002/lt.22044]

8. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. *Semin Liver Dis* 1999; 19: 329-338 [PMID: 10518312 DOI: 10.1055/s-2007-1007122]

9. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. *J Hepatol* 1999; 31: 133-141 [PMID: 10424293 DOI: 10.1016/S0168-8278(99)80173-1]

10. Farinati F, Vitale A, Spolverato G, Pawlik TM, Huo TL, Lee YH, Frigo AC, Giacobini A, Giannini EG, Ciccaresc F, Piscaglia F, Rappacini GL, Di Marco M, Catuliere E, Zoli M, Biorzi F, Cahibbo G, Feller M, Sacco R, Morisco F, Biasini E, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Masotto A, Trevisani F, Cillo U. ITA. LI.CA study group. Development and Validation of a New Prognostic System for Patients with Hepatocellular Carcinoma. *PLoS Med* 2016; 13: e1002006 [PMID: 27161206 DOI: 10.1371/journal.pmed.1002006]

11. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. *Hepatology* 1998; 28: 751-755 [PMID: 9731568 DOI: 10.1002/hep.50180232]

12. Sohn JH, Duran R, Zhao Y, Fleckenstein F, Chapiro J, Sahu S, Scherrnthuner RE, Qian T, Lee H, Zhao L, Hamilton J, Frangakis C, Lin M, Salem R, Gescher JP. Validation of the Hong Kong Liver Cancer Staging System in Determining Prognosis of the North American Patients Following Intra-arterial Therapy. *Clin Gastroenterol Hepatol* 2017; 15: 746-755.e4 [PMID: 27847278 DOI: 10.1016/j.cgh.2016.10.036]

13. Leong TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, Lau JT, Yu SC, Johnson P. Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. *Cancer* 2002; 94: 1760-1769 [PMID: 11920539 DOI: 10.1002/cncr.10384]

14. Kitai S, Kudo M, Minami Y, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T. Validation of a new prognostic staging system for hepatocellular carcinoma with biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. *Oncology* 2008; 75 Suppl 1: 83-90 [PMID: 19092276 DOI: 10.1159/000173428]

15. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. *Lancet* 2017; 391: 1301-1314 [PMID: 29307467 DOI: 10.1016/S0140-6736(18)30010-2]

16. Minagawa M, Makuuchi M. Treatment of hepatocellular carcinoma accompanied by portal vein tumor thrombus. *World J Gastroenterol* 2006; 12: 7561-7567 [PMID: 17171782 DOI: 10.3748/wjg.v12.i47.7561]

17. Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, Bru C, Rodés J, Bruix J. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. *Hepatology* 1999; 29: 62-67 [PMID: 9862851 DOI: 10.1002/hep.510290145]

18. Margini C, Berzigotti A. Portal vein thrombosis: The role of imaging in the clinical setting. *Dig Liver Dis* 2017; 49: 113-120 [PMID: 27965037 DOI: 10.1016/j.dld.2016.11.013]

19. Tessler FN, Gehring BJ, Gomes AS, Perrella RR, Ragavendra N, Busuttil RW, Grant EG. Diagnosis of portal vein thrombosis: value of color Doppler imaging. *AJR Am J Roentgenol* 1991; 157: 293-296 [PMID: 1853809 DOI: 10.2214/ajr.157.2.1853809]

20. Berzigotti A, Piscaglia F, EFISUMB Education and Professional Standards Committee. Ultrasound in portal hypertension–part 2–and EFSUMB recommendations for the performance and reporting of ultrasound examinations in portal hypertension. *Ultraschall Med* 2012; 33: 8-32; quiz 30-31 [PMID: 22222479 DOI: 10.1055/s-0031-129145]

21. Tarantino L, Francica G, Sordelli I, Esposito F, Giorgio A, Sorrentino P, de Stefano G, Di Sarro A, Ferrailo G, Sperlongano P. Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: color Doppler US, contrast-enhanced US, and fine-needle biopsy. *Abdom Imaging* 2006; 31: 537-544 [PMID: 16865315 DOI: 10.1007/s00261-005-0150-x]

22. Rosi S, Rosa L, Rovetta V, Cascina A, Quaretti P, Azzarelli A, Scagellini P, Tinelli C, Dionigi P, Calliada F. Contrast-enhanced versus conventional and color Doppler sonography for the detection of thrombosis of the portal and hepatic venous systems. *AJR Am J Roentgenol* 2006; 186: 763-773 [PMID: 16498104 DOI: 10.2214/AJR.04.1218]

23. Tublin ME, Dodd GD, Baron RL. Benign and malignant portal vein thrombosis: differentiation by CT characteristics. *AJR Am J Roentgenol* 1997; 168: 719-723 [PMID: 9057522 DOI: 10.2214/ajr.168.6.9057522]

24. Catalano OA, Choy G, Zhu A, Hahn PF, Sahani DV. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted
MR imaging. *Radiology* 2010; 254: 154-162 [PMID: 20032150 DOI: 10.1148/ radiol.09090304]

Sandeogaran K, Tahir B, Nutakki K, Aksikis FM, Bodanapally U, Tann M, Chalasani N. Usefulness of conventional MRI sequences and diffusion-weighted imaging in differentiating malignant from benign portal vein thrombus in cirrhotic patients. *AJR Am J Roentgenol* 2013; 201: 1211-1219 [PMID: 24261359 DOI: 10.2214/AJR.12.10171]

Canellas R, Mehrkhani F, Patino M, Kambadakone A, Sahani D. Characterization of Portal Vein Thrombosis (Neoplastic Versus Bland) on CT Images Using Software-Based Texture Analysis and Thrombus Density (Hounsfield Units). *AJR Am J Roentgenol* 2016; 207: W81-W87 [PMID: 27490995 DOI: 10.2214/AJR.15.15626]

Li C, Hu J, Zhou D, Zhao J, Ma K, Yin X, Wang J. Differentiation of bland from neoplastic thrombus of the portal vein in patients with hepatocellular carcinoma: application of susceptibility-weighted MR imaging. *BMC Cancer* 2014; 14: 590 [PMID: 25123782 DOI: 10.1186/1471-2407-14-590]

Rammohan A, Jawanth S, Sukumar R, Anand L, Kumar PS, Srinivasan UP, Ravi R, Ravichandran P. Percutaneous ultrasound-guided fine-needle aspiration of portal vein thrombus in a diagnostic and staging procedure for hepatocellular carcinoma. *Advmim Onco* 2013; 38: 1057-1060 [PMID: 23579929 DOI: 10.1007/s00261-013-9997-4]

Hu S, Zhang J, Cheng C, Liu Q, Sun G, Zuo C. The role of 18F-FDG PET/CT in differentiating malignant from benign portal vein thrombosis. *Advmim Onco* 2014; 39: 1221-1227 [PMID: 24913670 DOI: 10.1007/s00261-014-1070-5]

Ikai I, Arii S, Okazaki M, Oikita K, Omata M, Kojiro M, Takayasu K, Nakamura Y, Makuchi M, Matsuyama Y, Monden D, Kudo M. Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan. *Hepatol Res* 2007; 37: 676-691 [PMID: 17161712 DOI: 10.1111/j.1872-034X.2007.00119.x]

Ikai I, Itai Y, Oikita K, Omata M, Kojiro M, Kobayashi K, Nakamura Y, Futagawa S, Makuchi M, Yamaoka Y. Report of the 15th follow-up survey of primary liver cancer. *Hepatol Res* 2004; 28: 21-29 [PMID: 14734417 DOI: 10.1016/S0390-9012(03)08930.0002]

Shuqin C, Mengchao W, Han C, Feng S, Jiwei Y, Guanzhui D, Wenming C, Peijun W, Yuxiang Z. Tumor thrombus types influence the prognosis of hepatocellular carcinoma with the tumor thrombi in the portal vein. *Hepatogastroenterology* 2007; 54: 499-502 [PMID: 17523307]

Shi J, Lai EC, Li N, Guo WX, Xue J, Lau WY, Wu MC, Cheng SQ. A new classification for hepatocellular carcinoma with portal vein tumor thrombosis. *Hepatol Res* 2011; 41: 78-80 [PMID: 20686792 DOI: 10.1002/hep.24034-010.0314-01]

Xu JF, Liu XY, Wang S, Wen X. Surgical treatment for hepatocellular carcinoma with portal vein tumor thrombus: a novel classification. *World J Surg Oncol* 2015; 13: 86 [PMID: 25889711 DOI: 10.1186/s12957-015-0493-x]

Bruijs RA, Roel JA, Sherman M, Mazzaferrro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaumont CR, Sangiovanni A, Porta G, Gerken G, Natero D, Rasoul A, Shan M, Moscovici M, Volosits D, Llovet JM. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. *J Hepatol* 2012; 57: 821-829 [PMID: 22727733 DOI: 10.1016/j.jhep.2012.06.014]

Llovet JM, Ricci S, Mazzaferrro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Roel JA, Forman A, Schwartz M, Porta G, Zucconi M, Bertheau P, Baurin B, Hainsstat D, Qin S, Llovet JM. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subgroup analysis based on histological type. *Gut Liver* 2011; 5: 21-29 [PMID: 21618688 DOI: 10.4049/gutliver.10-0030]

Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Volosits D. Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2009; 10: 25-34 [PMID: 19005497 DOI: 10.1016/S1470-2045(08)70285-7]

Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, Yang TS, Tak WY, Pan H, Yu S, Xu J, Fang F, Zou J, Lentinii G, Volosits D, Kang YK. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subgroup analysis of the phase IIIb/Sorafenib Asia-Pacific trial. *Eur J Cancer* 2012; 48: 1452-1465 [PMID: 22420822 DOI: 10.1016/j.ejca.2011.12.006]

Yau T, Chan P, Ng KK, Chok SH, Cheung TT, Fan ST, Poon RT. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastases predicts poor response. *Cancer* 2009; 115: 428-436 [PMID: 19107763 DOI: 10.1002/cncr.24029]

Jeong SW, Jang YJ, Shin KY, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim KH, Kim JH. Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis. *Gut Liver* 2013; 7: 696-703 [PMID: 24312711 DOI: 10.5009/gnl.2013.7.6.696]

Giorgio A, Merola MG, Montessarchio L, Merola F, Santoro B, Corpolla C, Gatti P, Amendola E, Di Sarno A, Calvanese A, Matteucci P, Giorgio V. Sorafenib Combined with Radio-frequency Ablation Compared with Sorafenib Alone in Treatment of Hepatocellular Carcinoma Invading Portal Vein: A Western Randomized Controlled Trial. *Anticancer Res* 2016; 36: 6179-6183 [PMID: 27693949 DOI: 10.21873/anticancer.11211]

Park JW, Kim YJ, Kim DY, Bae SH, Paik SW, Lee YI, Kim HY, Lee HC, Han SY, Cheong YJ, Kwon OS, Yeon JH, Kim BH, Hwang J. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the Phase III STAH trial. *J Hepatol* 2019; 70: 684-691 [PMID: 30552937 DOI: 10.1016/j.jhep.2018.11.029]

Kudo M, Finn RS, Qin S, Han KJ, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komor E, Evans TRJ, Lopez C, Dulac D, Kang K, Maroun J, Guo M, Saito K, Taira M, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet* 2018; 391: 1163-1173 [PMID: 29433850 DOI: 10.1016/S0140-6736(18)30207-1]

Okada S, Okazaki N, Nose H, Yoshimori M, Aoki K. Prognostic factors in patients with hepatocellular carcinoma receiving systemic chemotherapy. *Hepatology* 1992; 16: 112-117 [PMID: 1773657 DOI: 10.1002/hep.1840160119]

Itamoto T, Nakahara H, Tashiro H, Haruta N, Asahara T, Naito A, Itok H. Hepatic arterial infusion of 5-fluourouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. *J Surg Oncol* 2002; 80: 143-148 [PMID: 12115797 DOI: 10.1002/jso.10116]

Yamazaki T, Kurokawa F, Shirahashi H, Kusano N, Hirokane K, Masuhara M, Okita K. Novel arterial
infusion chemotherapy using cisplatin, 5-fluorouracil, and leucovorin for patients with advanced hepatocellular carcinoma. *Hepatol Res* 2002; 23: 7-17 [PMID: 12084450 DOI: 10.1001/s1386-6346(01)00161-2]

47 Anda E, Yamashita F, Tanaka M, Tanikawa K. A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein. *Cancer* 1997; 79: 1890-1896 [PMID: 9149014 DOI: 10.1002/scti.10979105159703.0.CO;2-K]

48 Ura Be T, Kameko S, Matsushita E, Unoura M, Kobayashi K. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. *Oncology* 1998; 55: 39-47 [PMID: 9428374 DOI: 10.1159/00001833]

49 Kaneko S, Ura Be T, Kobayashi K. Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis. *Oncology* 2002; 62 Suppl 1: 69-73 [PMID: 11868789 DOI: 10.1159/00004227]

50 Sakon M, Nagano H, Dono K, Nakamori S, Umeshiba K, Yamada A, Kawata S, Imai Y, Iijima S, Monden M. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. *Cancer* 2002; 94: 435-442 [PMID: 11900229 DOI: 10.1002/cncr.10246]

51 Obi S, Yoshida H, Toune R, Unoura T, Kanda M, Sato S, Tateishi R, Teratani T, Shinya O, Omata M. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. *Cancer* 2006; 106: 1990-1997 [PMID: 16565970 DOI: 10.1002/cncr.21832]

52 Uta H, Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, Nakamura M, Dumdumsuren B, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshiba K, Nakamori S, Wakah K, Monden M. Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferon-alpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. *Br J Cancer* 2005; 93: 557-564 [PMID: 16106266 DOI: 10.1038/sj.bjc.6602742]

53 Song DS, Song MJ, Bae SH, Chung WJ, Jang JY, Kim YS, Lee SH, Park HY, Yim MJ, Cho SB, Park SY, Yang JM. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis. *J Gastroenterol* 2015; 50: 445-454 [PMID: 25027973 DOI: 10.1007/s00535-014-0978-3]

54 Ikeda M, Okusaka T, Furuie J, Mitsuakna S, Ueno H, Yamamura H, Inaba Y, Takeuchi Y, Satake M, Arai Y. A multi-institutional phase II trial of hepatic arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombosis. *Cancer Chemother Pharmacol* 2013; 72: 463-470 [PMID: 23812005 DOI: 10.1007/s00058-013-2223-x]

55 Kudo M, Takeuchi Y, Ueshima K, Yokosuka O, Obi S, Izuim N, Aikata H, Nagano H, Hatano E, Sasaki Y, Hino K, Kunuda K, Yamamoto K, Imai Y, Iwadou S, Ogawa C, Okusaka T, Arai Y, Kanai F, Akazawa K, and SIIUS Study Group. Prospective randomized controlled phase III trial comparing the efficacy of sorafenib versus sorafenib in combination with low-dose cisplatin/fluorouracil hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma. *J Hepatol* 2016; 64: S183-S12 [DOI: 10.1016/S0168-8278(16)00173-2]

56 Ikeda M, Shinmizu S, Takei T, Morigome M, Koizuma Y, Inaba Y, Hagiwara A, Kudo M, Nakamori S, Kaneko S, Sugimoto R, Tahara T, Unoura T, Yasai K, Sato K, Iishi H, Furuse J, Okusaka T. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial. *Ann Oncol* 2016; 27: 2090-2096 [PMID: 27573564 DOI: 10.1093/annonc/mdw323]

57 Yang H, Woo HY, Lee SK, Han JW, Jang B, Nam HC, Lee HL, Lee SW, Song DS, Song MJ, Oh JH, Chun HJ, Jang JW, Lozda A, Bae SH, Choi JY, Yoon SK. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function. *Clin Mol Hepatol* 2017; 23: 128-137 [PMID: 28494528 DOI: 10.3330/cmh.20160077]

58 Trevisani F, Brandi G, Garutti F, Barbera MA, Tortora R, Casadei Gardini A, Granito A, Tovoli F, De Lorenzo S, Inghilesi AL, Foschi FG, Bernardi M, Marra F, Sacco R, Di Costanzo GG. Metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function. *J Cancer Res Clin Oncol* 2018; 144: 403-414 [PMID: 29249050 DOI: 10.1007/s00432-017-2556-6]

59 European Association for the Study of the Liver; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. *J Hepatol* 2018; 69: 182-236 [PMID: 29622828 DOI: 10.1016/j.jhep.2018.03.019]

60 Liu L, Zhang C, Zhao Y, Qi D, Chen H, Bai W, He C, Guo W, Yin Z, Fan D, Han G. Transarterial chemembolization for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis: prognostic factors in a single-center study of 188 patients. *Biomed Res Int* 2014; 2014: 194278 [PMID: 24600212 DOI: 10.1155/2014/194278]

61 Yin J, Bo WT, Sun J, Xiang X, Lang JY, Zheng JH, Li LQ. New Evidence and Perspectives on the Management of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. *J Clin Transl Hepatol* 2017; 5: 169-176 [PMID: 28606155 DOI: 10.14288/JCTH.10600071]

62 Xue TC, Xie YY, Zhang L, Yin X, Zhang BH, Ren ZG. Transarterial chemembolization for hepatocellular carcinoma with portal vein tumor thrombus: a meta-analysis. *BMC Gastroenterol* 2013; 13: 60 [PMID: 23566041 DOI: 10.1186/1471-230X-13-60]

63 Leng JJ, Xu YZ, Dong JH. Efficacy of transarterial chemembolization for hepatocellular carcinoma with portal vein thrombosis: a meta-analysis. *ANZ J Surg* 2016; 86: 816-820 [PMID: 25088384 DOI: 10.1111/jans.12803]

64 Silva JP, Berger NG, Tsai S, Christians KK, Clarke CN, Mogal H, White S, Rilling W, Gamblin TC. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis. *HPB* (Oxford) 2017; 19: 659-666 [PMID: 28552299 DOI: 10.1016/j.hpb.2017.04.016]

65 Niu ZJ, Ma YL, Kang P, Ou SQ, Meng ZB, Li ZK, Qi F, Zhao C. Transarterial chemembolization compared with conservative treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: using a new classification. *Med Oncol* 2012; 29: 2992-2997 [PMID: 22509922 DOI: 10.1007/s12932-011-0145-0]

66 Chung GE, Lee JH, Kim HY, Hwang SY, Kim JS, Chung JW, Yoon JH, Lee HS, Kim YJ. Transarterial chemembranization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. *Radiology* 2011; 258: 627-634 [PMID: 21273254 DOI: 10.1148/radiol.10101058]
Treatment of HCC with PVTT

Ajit Y, Sudarsan H, Saumya G, Abhishek A, Navneet R, Piyush R, Anil A, Arun G. Transarterial chemoembolization in unresectable hepatocellular carcinoma with portal vein thrombosis: a perspective on survival. Oman Med J 2014; 29: 430-436 [PMID: 25384161 DOI: 10.5001/omj.2014.114]

Tawada A, Chiba T, Ooka Y, Kanogawa N, Motsayama T, Saito T, Osagawa S, Suzuki E, Maruyama H, Kani F, Yoshikawa M, Yokouka O. Efficacy of transarterial chemoembolization targeting portal vein tumor thrombus in patients with hepatocellular carcinoma. Anticancer Res 2014; 34: 4231-4237 [PMID: 25075052]

Sun J, Shu J, Huang B, Cheng F, Guo W, Lau WY, Cheng S. The degree of hepatic arterial blood supply of portal vein tumor thrombus in patients with hepatocellular carcinoma and its impact on overall survival after transarterial chemoembolization. Oncotarget 2017; 8: 79816-79824 [PMID: 29108363 DOI: 10.18632/oncotarget.19776]

Su J, Kim BJ, Lee TY. The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial. Int J Cancer 2015; 136: 1458-1467 [PMID: 25099027 DOI: 10.1002/ijc.29126]

Kim GA, Shim JH, Yoon SM, Jung J, Kim JH, Ryu MH, Ryoo BY, Kang YK, Lee D, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS. Comparison of chemembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. J Vasc Interv Radiol 2015; 26: 320-9.e4 [PMID: 25612818 DOI: 10.1016/j.jvir.2014.10.019]

Zhang XB, Wang JY, Yan ZP, Qian S, Du SS, Zeng ZC. Hepatocellular carcinoma with main portal vein involvement: treatment with 3-dimensional conformal radiotherapy after portal vein stenting and transarterial chemoembolization. Cancer 2009, 115: 1245-1252 [PMID: 19156918 DOI: 10.1002/crrm.21439]

Ichikura S, Ogino T, Funuse J, Satake M, Baba K, Kawashima M, Nihei K, Ito Y, Maru Y, Ikeeda H. Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol 2002; 25: 189-193 [PMID: 11943901 DOI: 10.1097/00000421-200204000-00019]

Huang YJ, Hsu HC, Wang CY, Wang CJ, Chen HC, Huang EY, Fang FM, Lu SN. The treatment responses in cases of radiation therapy to portal vein thrombosis in advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2009; 73: 1155-1163 [PMID: 18760547 DOI: 10.1016/j.ijrobp.2008.06.1486]

Kim DY, Park W, Lim DH, Lee JH, Yoo BC, Paik SW, Kho KC, Kim TH, Ahn YC, Huh SJ. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer 2005; 103: 2419-2426 [PMID: 15922310 DOI: 10.1002/cncr.21043]

Fujino H, Kimura T, Aikata H, Miyaki D, Kawao K, Kan H, Fukuhara T, Kobayashi T, Naeshiro N, Honda H, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Hyogo H, Takahashi S, Yoshimatsu R, Yamagami T, Kenjo M, Nagata Y, Awai K, Chayama K. Role of 3-D conformal radiotherapy for major portal vein tumor thrombus combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Hepatol Res 2015; 45: 607-617 [PMID: 25052365 DOI: 10.1111/hepr.12392]

Yu JJ, Park HC, Lim DH, Park WY. Predictive factors for Child-Pugh score elevation in hepatocellular carcinoma patients treated with conformal radiation therapy: dose-volume histogram analysis. Tumori 2013; 99: 164-171 [PMID: 23748809 DOI: 10.1700/1283.14187]

Lawrence TS, Ten Haken RK, Kessler ML, Robertson JM, Lyman JT, Livingle ML, Brown BB, DuRoss DJ, Andrews JC, Ensminger WD. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys 1992; 23: 781-788 [PMID: 1618671 DOI: 10.1016/0360-3016(92)90561-W]

Dawson LA, Ten Haken RK. Partial volume tolerance of the liver to radiation. Semin Radiat Oncol 2005; 15: 279-283 [PMID: 16183482 DOI: 10.1016/j.semradonc.2005.04.005]

Li N, Feng S, Xue J, Wei XJ, Shi J, Guo WX, Lu WX, Wu MC, Cerrito LQ, Meng Y. Hepatocellular carcinoma with main portal vein tumor thrombus: a comparative study comparing hepatectomy with or without neoadjuvant radiotherapy. HPB (Oxford) 2016; 18: 549-556 [PMID: 27317960 DOI: 10.1016/j.hpb.2016.04.003]

Tang QH, Li AJ, Yang GM, Lai EC, Zhou WP, Jiang ZH, Hui SJ. Comparison of chemoembolization with and without radiation therapy and sorafenib for resectable hepatocellular carcinoma with portal vein thrombus: a comparative study. World J Surg 2013; 37: 1362-1370 [PMID: 23456227 DOI: 10.1007/s00268-013-1969-x]

Lin CS, Jen YM, Chiu SY, Hung JM, Chao HL, Lin HY, Shum WY. Treatment of portal vein tumor thrombosis of hepatoma patients with either stereotactic radiotherapy or three-dimensional conformal radiotherapy. Jpn J Clin Oncol 2006; 36: 212-217 [PMID: 16613890 DOI: 10.1016/j.jjco.2006.01.005]

Hsu WC, Chan SC, Ting LL, Chung NN, Wang PM, Ying KS, Shin JS, Chao CJ, Lin GD. Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma. Jpn J Clin Oncol 2006; 36: 93-99 [PMID: 16517834 DOI: 10.1016/j.jjco.2005.06.005]

Lee JH, Kim DH, Ki YK, Nam JH, Heo J, Woo HY, Kim DW, Kim WT. Three-dimensional conformal radiotherapy for portal vein tumor thrombosis alone in advanced hepatocellular carcinoma. Radiat Oncol J 2014; 32: 170-178 [PMID: 25324989 DOI: 10.3857/roj.2014.32.3.170]

Toya R, Murakami R, Baba Y, Nishimura R, Morishita S, Ikeda O, Kawanaka K, Beppu T, Sugiyama S, Sakamoto T, Yanahashi Y, Oya N. Conformal radiation therapy for portal vein tumor thrombosis of hepatocellular carcinoma. Radiat Oncol J 2007; 24: 266-271 [PMID: 17176760 DOI: 10.1016/j.roj.2007.07.005]

Nakazawa T, Adachi S, Kitano M, Isobe Y, Kokubu S, Hidaka H, Oto K, Okuwaki Y, Watanabe M, Shibuya A, Saigenji K. Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to infrahepatic large vessels. Oncology 2007; 73: 90-97 [PMID: 18337620 DOI: 10.1159/000120996]
Kokubu S, Koizumi W. Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis. *BMC Gastroenterol* 2014; 14: 84 [PMID: 24886354 DOI: 10.1186/1471-230X-14-84].

Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Tokita M, Aibi M, Shoda J, Matsuzaki Y, Thono E, Tsboi K, Tokuney K. Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. *Strahlenther Onkol* 2009; 185: 782-788 [PMID: 20013087 DOI: 10.1007/s00066-009-2020-x].

Hata M, Tokuney K, Sugahara S, Kagei K, Igih K, Hashimoto T, Ohura K, Matsuzaki Y, Tanaka N, Akiue Y. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. *Cancer* 2005; 104: 794-801 [PMID: 15981284 DOI: 10.1002/cncr.21237].

Kim TH, Park JW, Kim BH, Kim H, Moon SH, Kim SS, Woo SM, Koh YH, Lee WJ, Kim DY, Kim CM. Does Risk-Adapted Proton Beam Therapy Have a Role as a Complementary or Alternative Therapeutic Option for Hepatocellular Carcinoma? *Cancers (Basel)* 2019; 11 [PMID: 30781391 DOI: 10.3390/cancers11020230].

Kim JY, Lim YK, Kim TH, Cho KH, Choi SH, Jeong H, Kim DW, Park JH, Shin DH, Lee SB, Kim SS, Kim JY, Kim DY, Park JW. Normal liver sparing by proton beam therapy for hepatocellular carcinoma: Comparison with helical intensity modulated radiotherapy and volumetric modulated arc therapy. *Acta Oncol* 2015; 54: 1827-1832 [PMID: 25765526 DOI: 10.3390/actaoncologi54041827].

Qi WX, Fu S, Zhang Q, Guo XM. Charged particle therapy versus photon therapy for patients with hepatocellular carcinoma: a systematic review and meta-analysis. *Radiother Oncol* 2015; 114: 289-295 [PMID: 25497556 DOI: 10.1016/j.radonc.2014.11.033].

Lu XJ, Dong J, Ji LJ, Luo JH, Cao HM, Xiao LX, Zhou J, Ling CQ. Safety and efficacy of TACE and gamma knife on hepatocellular carcinoma with portal vein invasion. *Gut* 2016; 65: 715-716 [PMID: 26268743 DOI: 10.1136/gutjnl-2015-310292].

Lu XJ, Dong J, Ji LJ, Xiao LX, Ling CQ, Zhou J. Tolerance and efficacy of gamma knife radiosurgery on hepatocellular carcinoma with portal vein tumor thrombosis. *Onciarteg* 2016; 7: 3614-3622 [PMID: 26477391 DOI: 10.18632/onciarteg.01118].

Chen SC, Lin SL, Chang WY. The effect of external radiotherapy in treatment of portal vein invasion in hepatocellular carcinoma. *Cancer Chemother Pharmacol* 1994; 33 Suppl: S124-S127 [PMID: 8137422 DOI: 10.1007/BF00686683].

Tazawa J, Maeda M, Sakai Y, Yamane M, Obbayaahi H, Kakinuma S, Miyasaka Y, Nagayama K, Enomoto N, Sato C. Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. *J Gastroenterol Hepatol* 2003; 18: 660-665 [PMID: 11422619 DOI: 10.1046/j.1440-1746.2001.02496.x].

Yamada K, Soejima T, Sugimoto K, Mayahara H, Izaki K, Sasaki R, Manuta T, Matsumoto S, Hirota S, Sugimura K. Pilot study of local radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. *Jpn J Clin Oncol* 2001; 31: 147-152 [PMID: 11386460 DOI: 10.1093/jjco/hye029].

Yu W, Gu K, Yu Z, Yuan D, He M, Ma N, Lai S, Zhao J, Ren Z, Zhang X, Shao C, Jiang GL. Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo. *Cancer Lett* 2013; 329: 109-117 [PMID: 2342289 DOI: 10.1016/j.canlet.2012.10.024].

Chen SW, Lin LC, Kuo YC, Liang FA, Kuo CC, Chios JF. Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys* 2014; 88: 1041-1047 [PMID: 24661657 DOI: 10.1016/j.ijrobp.2014.01.017].

Yoon SM, Lim YS, Won HJ, Kim JH, Kim KM, Lee HC, Chung YH, Lee YS, Lee SG, Park JH, Sah DJ. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. *Int J Radiat Oncol Biol Phys* 2012; 82: 2004-2011 [PMID: 2121346 DOI: 10.1016/j.ijrobp.2011.03.019].

Katamura Y, Aikata H, Takaki S, Azakami T, Kawaoka T, Waki K, Hiramatsu A, Kakinuma S, Shimizu S, Ohtsu M, Park JW, Kim SS, Lee SG, Park JH, Sah DJ. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. *Int J Radiat Oncol Biol Phys* 2012; 82: 2004-2011 [PMID: 2121346 DOI: 10.1016/j.ijrobp.2011.03.019].

Katamura Y, Aikata H, Takaki S, Azakami T, Kawaoka T, Waki K, Hiramatsu A, Kakinuma S, Shimizu S, Ohtsu M, Park JW, Kim SS, Lee SG, Park JH, Sah DJ. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. *Int J Radiat Oncol Biol Phys* 2012; 82: 2004-2011 [PMID: 2121346 DOI: 10.1016/j.ijrobp.2011.03.019].

Katamura Y, Aikata H, Takaki S, Azakami T, Kawaoka T, Waki K, Hiramatsu A, Kakinuma S, Shimizu S, Ohtsu M, Park JW, Kim SS, Lee SG, Park JH, Sah DJ. Radiotherapy plus transarterial chemoembolization for hepatocellular carcinoma invading the portal vein: long-term patient outcomes. *Int J Radiat Oncol Biol Phys* 2012; 82: 2004-2011 [PMID: 2121346 DOI: 10.1016/j.ijrobp.2011.03.019].

Akine Y. Proton beam therapy for hepatocellular carcinoma with portal vein tumor thrombus. *Strahlenther Onkol* 2013; 189: 782-788 [PMID: 20013087 DOI: 10.1007/s00066-009-2020-x].

She WH, Cheung TT, Yau TC, Chan AC, Chok KS, Chu FS, Liu RK, Poon RT, Chan SC, Fan ST, Lo CM. Survival analysis of transarterial radioembolization with yttrium-90 for hepatocellular carcinoma patients with HBV infection. *Heptobiliary Surg Nutr* 2014; 3: 185-193 [PMID: 25202695 DOI: 10.3978/j.issn.2304-3881.2014.07.09].

Salen R, Lewandowski RJ, Mulchay MF, Riaz A, Rya RK, Ibrahim S, Assisi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Ormary RA, Abecassis M, Kulik L. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. *Gastroenterology* 2010; 138: 52-64 [PMID: 19766639 DOI: 10.1053/j.gastro.2009.09.006].

Akinwande O, Kim D, Edwards J, Brown R, Philips P, Scoggin C, Martin RC 2nd. Is radioembolization ((90Y)) better than doxorubicin drug eluting beads (DEDBOX) for hepatocellular carcinoma with portal vein thrombosis? A retrospective analysis. *Surg Oncol* 2015; 24: 270-275 [PMID: 26135376 DOI: 10.1016/j.suronc.2015.06.008].

Edeline J, Crouzet L, Lezo-Gimenez B, Rolland Y, Pracht M, Guillaumonarch A, Boudjema K, Lenoir
Fukumoto T, Zhang YF, Inoue Y, Wu CC, Chok KS, Tanaka A, Sakamoto K, Lin TY, Tarantino L, Livraghi T, Chow PHW, Yang Y, Zheng JS, Lin TY, Lee CS, Chen KM, Chen CC. Role of surgery in the treatment of primary carcinoma of the liver: 30-year experience. Br J Surg 1987; 74: 839-842 [PMID: 282220] DOI: 10.1002/bjs.1800740101.

Yamakawa Y, Kudaka K, Ito K, Takayasu T, Shimahara Y, Mori K, Tanaka A, Morimoto T, Taki Y, Washida M. Liver resection for hepatocellular carcinoma (HCC) with direct removal of tumor thrombi in the main portal vein. World J Surg 1992; 16: 1172-6; discussion 1177 [PMID: 1333683].

Sakamoto K, Nagano H. Surgical treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus. Hepatol Res 2017; 47: 957-962 [PMID: 28681075 DOI: 10.1111/hepr.12923]

Tanaka A, Morimoto T, Yamakawa Y. Implications of surgical treatment for advanced hepatocellular carcinoma with tumor thrombi in the portal vein. Hepatogastroenterology 1996; 43: 637-643 [PMID: 879408].

Chok KS, Cheung TT, Chan SC, Poon RT, Fan ST, Lo CM. Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis. World J Surg 2014; 38: 490-496 [PMID: 24132826 DOI: 10.1007/s00268-013-2290-4].

Wu CC, Hsieh SR, Chen JT, Ho WL, Lin MC, Yeh DC, Liu TJ, P'eng FK. An appraisal of liver and portal vein resection for hepatocellular carcinoma with tumor thrombi extending to portal bifurcation. Arch Surg 2000; 135: 1273-1279 [PMID: 11074879].

Chang SL, Chong CC, Chan AW, Poon DM, Chok KS. Management of hepatocellular carcinoma with portal vein resection: Review and update at 2016. World J Gastroenterol 2016; 22: 7893-7900 [PMID: 27621575 DOI: 10.3748/wjg.v22.i32.7289].

Inoue Y, Hasegawa K, Ishiwashi T, Aoki T, Sano K, Beck Y, Imamura H, Sugawara Y, Kokudo N, Makuchii M. Is there any difference in survival according to the portal tumor thrombectomy method in patients with hepatocellular carcinoma? Surgery 2009; 145: 9-19 [PMID: 19081470 DOI: 10.1016/j.surg.2008.09.007].

Zhang YF, Le Y, Wei W, Zou RH, Wang JH, OuYang HY, Xiao CZ, Zhong XP, Shi M, Guo RP. Optimal surgical strategy for hepatocellular carcinoma with portal vein tumor thrombus: a propensity score analysis. Oncotarget 2016; 7: 38845-38856 [PMID: 27072575 DOI: 10.18632/oncotarget.8642].

Fukumoto T, Kido M, Takebe A, Tanaka M, Kinoshita K, Komatsu S, Tsugawa D, Goto T, Asari S, Toyama H, Ajiki T, Ku Y. New macroscopic classification and back-flow thrombectomy for advanced hepatocellular carcinoma with portal vein tumor thrombus invading the contralateral second portal branch. Surg Today 2017; 47: 1094-1103 [PMID: 28324163 DOI: 10.1007/s00595-017-1507-9].
Cerrito L et al. Treatment of HCC with PVTT

Hepatogastroenterology 2014; 61: 1696-1703 [PMID: 25436365]

Lim C, Compagnon P, Sebagh M, Salloum C, Calderaro J, Luciani A, Pascal G, Laurent A, Levesque E, Maggi U, Feray C, Cerequi D, Castaing D, Azoulay D. Hepatocellular carcinoma for patients with more than 10 cm. preoperative risk stratification to prevent futile surgery. HPB (Oxford) 2015; 17: 611-623 [PMID: 25980326 DOI: 10.1111/hpb.12416]

Torzilli G, Belghiti J, Kokudo N, Takayama T, Capsutti L, Nuzzo G, Vauthay JN, Choti MA, De Santibanes E, Donadon M, Morengi E, Makuchiu M. A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group. Ann Surg 2013; 257: 929-937 [PMID: 23426336 DOI: 10.1097/SLA.0b013e3182329988]

Wang JH, Wang CC, Hung CH, Chen CL, Lu SN. Survival comparison between surgical resection and radiofrequency ablation for patients in BCLC very/early-stage hepatocellular carcinoma. J Hepatol 2012; 56: 412-418 [PMID: 22156838 DOI: 10.1016/j.jhep.2011.05.021]

Kumada K, Ozawa K, Okamoto R, Takayasu T, Yamaguchi M, Yamamoto Y, Higashiyama H, Morikawa S, Sasaki H, Shimahara Y. Hepatic resection for advanced hepatocellular carcinoma with removal of portal vein tumor thrombi. Surgery 1990; 108: 821-827 [PMID: 2173162]

Zhong JH, Torzilli G, Xing H, Li C, Han J, Liang L, Zhang H, Dai SY, Li LQ, Shen F, Yang T. Controversies and evidence of hepatic resection for hepatocellular carcinoma. BJA Clin 2016; 125: 125-130

Zhong JH, Rodriguez AC, Ke Y, Wang YY, Wang L, Li LQ. Hepatic resection as a safe and effective treatment for hepatocellular carcinoma involving a single large tumor, multiple tumors, or macrovascular invasion. Medicine (Baltimore) 2015; 94: e396 [PMID: 26261684 DOI: 10.1097/MD.0000000000003964]

Peng ZW, Guo RP, Zhang YJ, Lin XJ, Chen MS, Lau WY. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Cancer 2012; 118: 4725-4736 [PMID: 22359112 DOI: 10.1002/cncr.26561]

Shi J, Lai EC, Li N, Guo WX, Xue J, Lau WY, Wu MC, Cheng SQ. Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus. Ann Surg Oncol 2010; 17: 2073-2080 [PMID: 2031013DOI: 10.1245/s10434-010-0940-4]

Liu PH, Lee YH, Hisa CY, Hsia CY, Huang YH, Chiu YY, Lin HC, Hau TL. Surgical resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. Ann Surg Oncol 2014; 21: 1825-1833 [PMID: 24499831 DOI: 10.1245/s10434-014-0570-z]

Zheng N, Wei X, Zhang D, Chai W, Che M, Wang J, Du B. Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus. Medicine (Baltimore) 2016; 95: e3959 [PMID: 27367992 DOI: 10.1097/MD.0000000000003959]

Chen XP, Quo FZ, Wu ZD, Zhang ZW, Huang ZY, Chen YF, Zhang BX, He SQ, Zhang WG. Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma. Ann Surg Oncol 2006; 13: 940-946 [PMID: 16788755 DOI: 10.1245/ASO.2006.08.007]

Kudo M, Izumi N, Ichida T, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Matsui O, Matsuyama Y. Report of the 19th follow-up survey of primary liver cancer in Japan. Hepatol Res 2016; 46: 372-390 [PMID: 26970231 DOI: 10.1111/hepr.12697]

Ban D, Shimada K, Yamamoto Y, Nara S, Esaki M, Sakamoto Y, Kosuge T. Efficacy of a hepatectomy and a tumor thrombectomy for hepatocellular carcinoma with tumor thrombus extending to the main portal vein. J Gastrointest Surg 2009; 13: 1921-1928 [PMID: 19727960 DOI: 10.1007/s11605-009-0998-0]

Giantzounis GK, Paloureas A, Stylianidi MC, Milionis H, Trizmas P, Roukos D, Pentheroudakis G, Fakelouras E. The role of liver resection in the management of intermediate and advanced stage hepatocellular carcinoma. A systematic review. Eur J Surg Oncol 2018; 44: 195-208 [PMID: 29258719 DOI: 10.1016/j.ejso.2017.11.022]

Wang K, Guo WX, Chen MS, Mao YL, Sun BC, Shi J, Zhang YJ, Meng Y, Yang YF, Cong WM, Wu MC, Lau WY, Cheng SQ. Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Propensity Matched-Set Analysis. Medicine (Baltimore) 2016; 95: e3015 [PMID: 26966115 DOI: 10.1097/MD.0000000000003015]

Higaki T, Yamazaki S, Moriguichi M, Nakayama H, Kurokawa T, Takayama T. Indication for surgical resection in patients with hepatocellular carcinoma with major vascular invasion. Biosci Trends 2017; 11: 581-587 [PMID: 29021421 DOI: 10.5582/bst.2017.01210]

Yamamoto Y, Ikoma H, Morimura R, Shoda K, Konishi H, Murayama Y, Komatsu S, Shiozaki A, Kuriu Y, Kubota T, Nakamushi I, Ichikawa D, Fujihara W, Okamoto K, Sakakura C, Ohchi T, Otsui E. Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol 2015; 21: 246-253 [PMID: 25574098 DOI: 10.3748/wjg.v21.i1.246]

Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-1474 [PMID: 20180029 DOI: 10.1245/s10434-010-0985-4]

Pesi B, Ferrero A, Grazì GL, Crescen M, Russolillo N, Leo F, Boni L, Pinna AD, Capussotti L, Bagianni G. Liver resection with thrombectomy as a treatment of hepatocellular carcinoma with major vascular invasion: results from a retrospective multicentric study. Ann J Surg 2015; 210: 35-44 [PMID: 25932229 DOI: 10.1016/j.amjsurg.2014.09.041]

Roayaie S, Jibara G, Taouli B, Schwartz M. Resection of hepatocellular carcinoma with macroscopic vascular invasion. Ann Surg Oncol 2013; 20: 3754-3760 [PMID: 23884750 DOI: 10.1245/s10434-013-3047-4]

Iyun MH, Lee YS, Kim JH, Lee CU, Jung YK, Seo YS, Yim HJ, Yeon JE, Byun KS. Hepatic resection compared to chemoembolization in intermediate- to advanced-stage hepatocellular carcinoma: A meta-analysis of high-quality studies. Hepatology 2018; 68: 977-993 [PMID: 29543988 DOI: 10.1002/hep.29883]

Zhang XP, Guo YZ, Chen ZH, Chen MS, Li LQ, Wen TF, Xu L, Wang K, Chai ZT, Guo WX, Shi J, Xie D, Wu MC, Yee Lau W, Cheng SQ. An Eastern Hepatobiliary Surgery Hospital/Portal Vein Tumor Thrombus Scoring System as an Aid to Decision Making on Hepatectomy for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: A Multicenter Study. Hepatology 2019; 69: 2067-2090 [PMID: 30586158 DOI: 10.1002/hep.30490]

Schnitzbauer AA, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA, Fichtner-Feigl S, Lorf T, Goelz A, Hörbelt R, Kroemer A, Loss M, Rümmele P, Scherer MN, Padberg W, Königrainer A, Lang
H, Obed A, Schlitt HJ. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 2012; 255: 405-414 [PMID: 22308083 DOI: 10.1097/Sla.0b013e3182485d5f]

Vennareci G, Laurenzi A, Santoro R, Colasanti M, Leptane P, Ettorre GM. The ALPPS procedure: a surgical option for hepatocellular carcinoma with major vascular invasion. World J Surg 2014; 38: 1498-1503 [PMID: 24146197 DOI: 10.1007/s00268-013-2296-y]

Kamiyama T, Kikasaka T, Orimo T, Wakayama K. Hepatectomy for hepatocellular carcinoma with portal vein tumor thrombus. World J Hepatol 2017; 9: 1296-1304 [PMID: 29395012 DOI: 10.26915/wjhe.v9.i13.1296]

Ye JZ, Wang YY, Bai T, Chen J, Xiang BD, Wu FX, Li LQ. Surgical resection for hepatocellular carcinoma with portal vein tumor thrombosis in the Asia-Pacific region beyond the Barcelona Clinic Liver Cancer treatment algorithms: a review and update. Oncotarget 2017; 8: 93528-93528 [PMID: 29190996 DOI: 10.18632/oncotarget.18735]

Peng BG, He GJ, Li JP, Zhou F. Adjuvant transcatheter arterial chemoembolization improves efficacy of hepatectomy for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Surg 2009; 198: 313-318 [PMID: 19285298 DOI: 10.1016/j.amjsurg.2008.09.026]

Li Q, Wang J, Sun Y, Cui YL, Juzi JT, Li HX, Qian BY, Hao XS. Efficacy of postoperative transarterial chemoembolization and portal vein chemotherapy for patients with hepatocellular carcinoma complicated by portal vein tumor thrombosis—a randomized study. World J Surg 2006; 30: 2004-2011; discussion 2012-2013 [PMID: 17058027 DOI: 10.1002/wjsg.6027-6027]

Fukuda S, Okuda K, Inamura M, Inamura I, Eriguchi N, Aoyagi S. Surgical resection combined with chemotherapy for advanced hepatocellular carcinoma with tumor thrombus: report of 19 cases. Surgery 2002; 131: 390-391 [PMID: 11894035 DOI: 10.1067/msy.2002.126668]

Lau WY, Ho SK, Yu SC, Lai EC, Liew CT, Leung T, Salvage surgery following down staging of unresectable hepatocellular carcinoma. Ann Surg 2004; 240: 299-305 [PMID: 12723555 DOI: 10.1097/01.sla.0000133123.11932.19]

Kamiyama T, Nakamichi K, Yoko H, Tahara M, Nakagawa T, Kamachi H, Taguchi H, Shirato H, Matsushita M, Todo S. Efficacy of preoperative radiation therapy to portal vein tumor thrombus in the main trunk or first branch in patients with hepatocellular carcinoma. Int J Clin Oncol 2007; 12: 363-368 [PMID: 17929118]

Pracht M, Edeline J, Lenoir X, Latourmerge M, Mossip H, Adrían O, Rolland Y, Clément B, Roaul JL, Garnin E, Boucher E. Lobar hepatocellular carcinoma with ipsilateral portal vein tumor thrombosis treated with yttrium-90 glass microsphere radioembolization: preliminary results. Int J Hepatol 2013; 2013: 827649 [PMID: 23476792 DOI: 10.1155/2013/827649]

Feng YX, Wang T, Deng YZ, Yang P, Li JJ, Guan DX, Yao F, Zhu YQ, Qin Y, Wang H, Li N, Wu MC, Wang WH, Wang XF, Cheng SX, Xie D. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model. Hepatology 2011; 53: 483-492 [PMID: 21248700 DOI: 10.1002/hep.24002]

Li J, Hou Y, Cai XB, Liu B. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma. World J Gastroenterol 2016; 22: 4034-4040 [PMID: 27094447 DOI: 10.3748/wjg.v22.i15.4034]

Tang ZY, Zhou BH, Wang W, Du G, Liu ZY, Li J, Zhang SZ, Fu ZH. Curative Analysis of Several Therapeutic Methods for Primary Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Hepatogastroenterology 2015; 62: 703-709 [PMID: 26897958]

Nagano H, Kobayashi S, Marubashi S, Wada H, Eguchi H, Tanemura M, Tomimaru Y, Umetsu K, Doki Y, Morii M. Combined IFN-α and 5-FU treatment as a postoperative adjuvant following surgery for hepatocellular carcinoma with portal venous tumor thrombus. Exp Ther Med 2013; 5: 3-10 [PMID: 23251233 DOI: 10.3892/etm.2012.736]

Choi HJ, Kim DG, Na GH, Hong TH, You YK. Extended criteria for living donor liver transplantation in patients with advanced hepatocellular carcinoma. Transplant Proc 2012; 44: 399-402 [PMID: 22410027 DOI: 10.1016/transpro.2012.01.019]

Freeman BB. Transplantation for hepatocellular carcinoma: The Milan criteria and beyond. Liver Transpl 2006; 12: S8-13 [PMID: 17051567 DOI: 10.1002/lt.20936]

Kaihara S, Kikuchi T, Ueda M, Oike F, Fujimoto Y, Ogawa K, Kozaki K, Tanaka K. Living-donor liver transplantation for hepatocellular carcinoma. Transplantation 2003; 75: S37-S40 [PMID: 12589138 DOI: 10.1097/01.TP.0000047029.02806.16]

Sapiogich G, Goldaracena N, Laurence JM, Dib M, Barbas A, Ghanekar A, Cleary SP, Lilly L, Cattral MS, Marquez M, Selzner M, Renner E, Selzner N, McGilvray ID, Greig PD, Grant DR. The extended criteria for living donor transplantation for hepatocellular carcinoma. World J Gastroenterol 2016; 22: 5763-5768 [PMID: 27178460 DOI: 10.1002/hep.28643]

Hao DH, Joo DJ, Kim MS, Choi GH, Choi JS, Park YN, Seong J, Han KH, Kim SI. Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy. Yonsei Med J 2016; 57: 1276-1281 [PMID: 27401664 DOI: 10.3349/ymj.2016.57.5.1276]

Levi Sandri GB, Ettorre GM, Colasanti M, De Werra E, Mascianà G, Ferrando D, Tortorelli G, Sciotto R, Lucatti P, Pizzi G, Visco-Comandini U, Vanzetto R, Santoro R. Hepatocellular carcinoma with macrovascular invasion treated with yttrium-90 radioembolization prior to transplantation. Hepatobiliary Surg Nutr 2017; 6: 44-48 [PMID: 28261594 DOI: 10.21037/hbsn.2017.01.08]

Chino F, Stephens SJ, Choi SS, Marin D, Kim CY, Morse MA, Godfrey DJ, Czito BG, Willett CG, Palta M. The role of external beam radiotherapy in the treatment of hepatocellular cancer. Cancer 2018; 124: 3476-3489 [PMID: 29645076 DOI: 10.1002/cncr.31334]

Mannina EM, Cardenes HR, Lasley FD, Goodman B, Zook J, Althouse S, Cox JA, Saxena R, Tector J, Maluccio M. Role of Stereotactic Body Radiation Therapy Before Orthotopic Liver Transplantation: Retrospective Evaluation of Pathologic Response and Outcomes. Int J Radiat Oncol Biol Phys 2017; 97: 931-938 [PMID: 28333015 DOI: 10.1016/j.ijrobp.2016.12.036]

O’Connor JK, Trottier J, Davis GL, Dempster J, Klimtmalm GB, Goldstein RM. Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantation. Liver Transpl 2012; 18: 949-954 [PMID: 22467602 DOI: 10.1002/hep.23439]

Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecasis MM, Roberts LR, Zhu AX, Marad MH, Marrero JA. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67: 358-380 [PMID: 28130846 DOI: 10.1002/hep.29886]
Cerrito L et al. Treatment of HCC with PVTT

181 Wang HL, Cucchetti A, Zhong JH, Ye XP, Gu JH, Ma L, Peng NF, Li LQ. Should hepatic resection be recommended to patients with hepatocellular carcinoma and portal vein invasion? *J Hepatol* 2016; 65: 1057-1058 [PMID: 27475616 DOI: 10.1016/j.jhep.2016.07.022]

182 Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, Kudo M, Ku Y, Sakamoto M, Nakashima O, Kaneko S, Kokudo N. Liver Cancer Study Group of Japan. Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. *J Hepatol* 2016; 65: 938-943 [PMID: 27266618 DOI: 10.1016/j.jhep.2016.05.044]
